Statera Biopharma (STAB) 10-K 17 Mar 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Mar. 14, 2014	Jun. 30, 2013
Document And Entity Information [Abstract]	'	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Entity Registrant Name	'CLEVELAND BIOLABS INC	'	'
Entity Central Index Key	'0001318641	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Entity Filer Category	'Accelerated Filer	'	'
Entity Common Stock, Shares Outstanding	'	50,919,820	'
Entity Public Float	'	'	$65,171,586

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
Current assets:	'	'
Cash and cash equivalents	$10,048,466	$25,652,083
Short-term investments	305,538	2,633,944
Accounts receivable	458,391	41,896
Other current assets	344,386	1,078,040
Total current assets	11,156,781	29,405,963
Equipment, net	457,912	986,553
Restricted cash	2,921,724	1,577,920
Other long-term assets	159,224	39,597
Total assets	14,695,641	32,010,033
Current liabilities:	'	'
Accounts payable	794,397	1,523,875
Accrued expenses	2,445,446	2,410,592
Deferred revenue	1,069,438	3,314,918
Accrued warrant liability	1,241,311	4,105,659
Current portion of note payable	351,527	'
Current portion of capital lease obligation	83,634	71,679
Total current liabilities	5,985,753	11,426,723
Noncurrent portion of capital lease obligation	7,522	97,602
Long-term debt	7,121,388	'
Commitments and contingencies	'	'
Total liabilities	13,114,663	11,524,325
Stockholders' equity:	'	'
Preferred stock, $.005 par value; 10,000,000 shares authorized, 0 shares issued and outstanding as of December 31, 2013 and December 31, 2012, respectively	'	'
Common stock, $.005 par value; 160,000,000 shares authorized, 45,182,114 shares issued and outstanding as of December 31, 2013; 80,000,000 shares authorized, 44,730,445 issued and outstanding as of December 31, 2012	225,911	223,653
Additional paid-in capital	125,508,471	123,864,830
Accumulated other comprehensive income	307,339	546,473
Accumulated deficit	-135,564,666	-118,301,789
Total Cleveland BioLabs, Inc. stockholders' (deficit) equity	-9,522,945	6,333,167
Noncontrolling interest in stockholders' equity	11,103,923	14,152,541
Total stockholders' equity	1,580,978	20,485,708
Total liabilities and stockholders' equity	$14,695,641	$32,010,033

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Statement Of Financial Position [Abstract]	'	'
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	160,000,000	80,000,000
Common stock, shares issued	45,182,114	44,730,445
Common stock, shares outstanding	45,182,114	44,730,445

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Revenues:	'	'	'
Grants and contracts	$8,487,966	$3,570,710	$8,790,209
Operating expenses:	'	'	'
Research and development	19,525,950	22,501,805	22,788,887
General and administrative	12,038,775	11,115,511	11,106,493
Total operating expenses	31,564,725	33,617,316	33,895,380
Loss from operations	-23,076,759	-30,046,606	-25,105,171
Other income:	'	'	'
Interest and other income (expense)	83,127	-70,015	53,659
Change in value of warrant liability	2,864,348	7,701,981	19,821,787
Total other income	2,947,475	7,631,966	19,875,446
Net loss	-20,129,284	-22,414,640	-5,229,725
Net loss attributable to noncontrolling interests	2,866,407	4,180,498	1,216,055
Net loss attributable to Cleveland BioLabs, Inc.	($17,262,877)	($18,234,142)	($4,013,670)
Net loss available to common stockholders per share of common stock, basic and diluted	($0.38)	($0.49)	($0.12)
Weighted average number of shares used in calculating net loss per share, basic and diluted	45,002,823	37,388,847	32,561,743

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Loss (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Statement Of Income And Comprehensive Income [Abstract]	'	'	'
Net loss including noncontrolling interests	($20,129,284)	($22,414,640)	($5,229,725)
Other comprehensive income (loss):	'	'	'
Foreign currency translation adjustment	-421,345	797,558	153,815
Comprehensive loss including noncontrolling interests	-20,550,629	-21,617,082	-5,075,910
Comprehensive loss attributable to noncontrolling interests	3,048,618	3,844,800	1,177,397
Comprehensive loss attributable to Cleveland BioLabs, Inc.	($17,502,011)	($17,772,282)	($3,898,513)

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Cash flows from operating activities:	'	'	'
Net income (loss)	($20,129,284)	($22,414,640)	($5,229,725)
Adjustments to reconcile net income (loss) to net cash used in operating activities:	'	'	'
Depreciation	376,213	479,595	512,366
Amortization	94,995	'	13,147
Unrealized currency loss on short-term investments	'	52,726	'
(Gain) loss on equipment disposal	-3,222	18,997	'
Impairment loss on property and equipment	293,162	'	'
Noncash compensation	1,473,449	2,535,217	4,044,858
Warrant issuance costs	'	244,857	150,827
Change in value of warrant liability	-2,864,348	-7,701,981	-19,821,787
Patent costs	'	'	1,481,318
Changes in operating assets and liabilities:	'	'	'
Accounts receivable	-416,495	1,736,199	3,641,491
Other current assets	697,966	-182,428	123,197
Other long-term assets	-29,732	-6,414	-919
Accounts payable	-713,502	609,522	-348,282
Deferred revenue	-2,062,332	3,238,124	-2,317,218
Accrued expenses	180,483	740,723	845,337
Net cash used in operating activities	-23,102,647	-20,649,503	-16,905,390
Cash flows from investing activities:	'	'	'
Purchase of short-term investments	'	-5,220,781	-5,520,000
Sale of short-term investments	2,197,940	8,312,120	434,835
Purchase of equipment	-139,491	-178,271	-655,553
Increase in restricted cash	-1,497,740	-1,541,366	'
Investment in patents	'	'	-326,171
Net cash provided by (used in) investing activities	560,709	1,371,702	-6,066,889
Cash flows from financing activities:	'	'	'
Issuance of common stock, net of offering costs	'	15,675,727	21,946,801
Net proceeds from issuance of debt	7,327,675	'	'
Exercise of options	12,392	2,375	532,408
Repayment of capital lease obligation	-78,125	-52,410	'
Exercise of warrants	'	'	949,793
Net cash provided by financing activities	7,261,942	21,519,249	34,769,442
Effect of exchange rate change on cash and cash equivalents	-323,621	538,046	156,889
Increase (decrease) in cash and cash equivalents	-15,603,617	2,779,494	11,954,052
Cash and cash equivalents at beginning of period	25,652,083	22,872,589	10,918,537
Cash and cash equivalents at end of period	10,048,466	25,652,083	22,872,589
Supplemental disclosure of cash flow information:	'	'	'
Cash paid during the period for interest	128,811	23,708	'
Supplemental schedule of noncash financing activities:	'	'	'
Fair value of warrants issued in connection with debt	117,999	'	'
Equipment acquired through lease financing	'	221,690	'
Conversion of warrant liability to equity upon warrant exercise	'	'	995,428
Noncash financing costs on common stock offering	'	'	207,905
Noncash warrant issuance costs	'	'	19,361
Incuron, LLC [Member]	'	'	'
Cash flows from financing activities:	'	'	'
Noncontrolling interest capital contribution	'	5,893,557	2,340,374
Panacela [Member]	'	'	'
Cash flows from financing activities:	'	'	'
Noncontrolling interest capital contribution	'	'	$9,000,066

Consolidated_Statement_of_Shar

Consolidated Statement of Shareholders' Equity (USD $)	Total	Incuron, LLC [Member]	Panacela [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]	Noncontrolling Interest [Member]	Noncontrolling Interest [Member]	Noncontrolling Interest [Member]
						Incuron, LLC [Member]				Incuron, LLC [Member]	Panacela [Member]
Beginning balance at Dec. 31, 2010	($12,500,135)	'	'	$144,796	$80,241,717	'	($30,544)	($96,053,977)	$3,197,873	'	'
Beginning balance, shares at Dec. 31, 2010	'	'	'	28,959,176	'	'	'	'	'	'	'
Issuance of common stock net of offering costs	21,870,362	'	'	29,363	21,840,999	'	'	'	'	'	'
Issuance of common stock net of offering costs, shares	'	'	'	5,872,500	'	'	'	'	'	'	'
Allocation of debt and financing proceeds to fair value of warrants	-2,525,175	'	'	'	-2,525,175	'	'	'	'	'	'
Noncontrolling interest capital contribution	176,092	2,340,374	9,000,066	'	'	176,092	'	'	'	2,164,282	9,000,066
Stock based compensation	6,658,286	'	'	1,544	6,656,742	'	'	'	'	'	'
Stock based compensation, shares	'	'	'	308,850	'	'	'	'	'	'	'
Exercise of options	532,408	'	'	951	531,457	'	'	'	'	'	'
Exercise of options, shares	'	'	'	190,255	'	'	'	'	'	'	'
Exercise of warrants	1,945,220	'	'	1,407	1,943,813	'	'	'	'	'	'
Exercise of warrants, shares	'	'	'	281,411	'	'	'	'	'	'	'
Net loss	-5,229,725	'	'	'	'	'	'	-4,013,670	-1,216,055	'	'
Foreign currency translation	153,815	'	'	'	'	'	115,157	'	38,658	'	'
Ending balance at Dec. 31, 2011	22,245,496	'	'	178,061	108,865,645	'	84,613	-100,067,647	13,184,824	'	'
Ending balance, shares at Dec. 31, 2011	'	'	'	35,612,192	'	'	'	'	'	'	'
Issuance of common stock net of offering costs	15,920,584	'	'	42,625	15,877,959	'	'	'	'	'	'
Issuance of common stock net of offering costs, shares	'	'	'	8,525,000	'	'	'	'	'	'	'
Allocation of debt and financing proceeds to fair value of warrants	-4,521,681	'	'	'	-4,521,681	'	'	'	'	'	'
Noncontrolling interest capital contribution	1,081,040	5,893,557	'	'	'	1,081,040	'	'	'	4,812,517	'
Stock based compensation	2,562,459	'	'	2,961	2,559,498	'	'	'	'	'	'
Stock based compensation, shares	'	'	'	592,003	'	'	'	'	'	'	'
Exercise of options	2,375	'	'	6	2,369	'	'	'	'	'	'
Exercise of options, shares	'	'	'	1,250	'	'	'	'	'	'	'
Net loss	-22,414,640	'	'	'	'	'	'	-18,234,142	-4,180,498	'	'
Foreign currency translation	797,558	'	'	'	'	'	461,860	'	335,698	'	'
Ending balance at Dec. 31, 2012	20,485,708	'	'	223,653	123,864,830	'	546,473	-118,301,789	14,152,541	'	'
Ending balance, shares at Dec. 31, 2012	'	'	'	44,730,445	'	'	'	'	'	'	'
Allocation of debt and financing proceeds to fair value of warrants	117,999	'	'	'	117,999	'	'	'	'	'	'
Stock based compensation	1,515,509	'	'	2,210	1,513,299	'	'	'	'	'	'
Stock based compensation, shares	'	'	'	441,988	'	'	'	'	'	'	'
Exercise of options	12,391	'	'	48	12,343	'	'	'	'	'	'
Exercise of options, shares	9,681	'	'	9,681	'	'	'	'	'	'	'
Net loss	-20,129,284	'	'	'	'	'	'	-17,262,877	-2,866,407	'	'
Foreign currency translation	-421,345	'	'	'	'	'	-239,134	'	-182,211	'	'
Ending balance at Dec. 31, 2013	$1,580,978	'	'	$225,911	$125,508,471	'	$307,339	($135,564,666)	$11,103,923	'	'
Ending balance, shares at Dec. 31, 2013	'	'	'	45,182,114	'	'	'	'	'	'	'

Consolidated_Statement_of_Shar1

Consolidated Statement of Shareholders' Equity (Parenthetical) (Common Stock [Member], USD $)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Common Stock [Member]	'	'
Issuance of common stock	$1,129,916	$1,619,638

Description_of_Business

Description of Business	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Description of Business	'
	1. Description of Business
	Cleveland BioLabs, Inc. is an innovative drug development company seeking to develop first-in-class pharmaceuticals designed to address diseases with significant unmet medical need. Our programs are focused on the implementation of novel pharmacological approaches to control cell death. As used throughout these consolidated financial statements, the terms “Cleveland BioLabs” and “CBLI” refer to Cleveland BioLabs, Inc., but not its consolidated subsidiaries and “the Company,” “we,” “us” and “our” refer to Cleveland BioLabs, Inc. together with its consolidated subsidiaries.
	CBLI was incorporated in Delaware in June 2003 and is headquartered in Buffalo, New York. CBLI has one wholly-owned operating subsidiary, BioLab 612, LLC, or BioLab 612, which began operations in 2012. CBLI has two majority-owned operating subsidiaries, Incuron, LLC, or Incuron, and Panacela Labs, Inc., or Panacela, which were formed in 2010 and 2011, respectively. Additionally, Panacela has a wholly-owned operating subsidiary, Panacela Labs, LLC.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	2. Summary of Significant Accounting Policies
	Basis of Presentation and Consolidation
	The accompanying consolidated financial statements include the accounts of CBLI and its subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. These financial statements have been prepared on the accrual basis in accordance with accounting principles generally accepted in the United States, or GAAP.
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
	Cash and Cash Equivalents
	Of the $10 million and $25.7 million of cash and cash equivalents at December 31, 2013 and December 31, 2012, respectively, $3.5 million and $13.0 million, respectively, consisted of highly liquid investments with maturities of 90 days or less when purchased. These investments consist of commercial paper, short-term debt securities, time deposits and investments in money market funds with commercial banks and financial institutions. As of December 31, 2013, $2.0 million of the Company’s cash and cash equivalents were restricted to the use of its majority-owned subsidiaries, leaving $8.0 million available for general use.
	Short-Term Investments
	The Company’s short-term investments are classified as held to maturity given the intent and ability to hold the investments to maturity. Accordingly, these investments are carried at amortized cost. Short-term investments classified as held-to-maturity consisted of certificates of deposit with maturity dates beyond three months and less than one year. As of December 31, 2013, all of the Company’s short-term investments were restricted for use by its majority-owned subsidiaries.
	Concentrations of Credit Risk
	Financial instruments that potentially subject the Company to a significant concentration of credit risk primarily consist of cash and cash equivalents and short-term investments. The Company maintains cash balances with financial institutions in excess of insured limits. The Company does not believe it is exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.
	As of December 31, 2013, the Company held 36% of its cash and cash equivalents and 100% of its short-term investments in accounts located outside of the United States.
	As of March 11, 2014, the Russian Ruble exchange rate increased from $32.2792 to $36.2618, resulting in a decrease of $350,557 to the Company’s cash and cash equivalents and $29,765 to the Company’s short-term investment balances as compared to December 31, 2013.
	Significant Customers and Accounts Receivable
	Grant and contract revenue from the United States government accounted for 26.8%, 34.8% and 87.6% of total revenue for the years ended December 31, 2013, 2012 and 2011, respectively. The Company anticipates that its sources of revenue in the near future will be from development contracts from the United States and Russian federal governments, however there is no guarantee that this revenue stream will continue in the future.
	Grant and contract revenue received by our subsidiaries from Russian government agencies accounted for 73.2%, 65.2% and 12.4% of total revenues for the years ended December 31, 2013, 2012 and 2011, respectively.
	Accounts receivable consist of amounts due under contracts with certain government and foreign entities. The Company extends unsecured credit to its government customers under normal trade agreements and contracted terms, which generally require payment within 30 days.
	Management estimates an allowance for doubtful accounts that is based upon management’s review of delinquent accounts and an assessment of the Company’s historical evidence of collections. There were no allowances for doubtful accounts as of December 31, 2013 and 2012, as the collection history from the Company’s customers indicated that collection was probable.
	Equipment
	Equipment is stated at cost, net of accumulated depreciation. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repair and maintenance costs are expensed as incurred.
	Equipment is depreciated using the straight-line method over the estimated useful lives of the respective assets as follows:
	Asset Category	Estimated Useful Life
		(in Years)
	Laboratory equipment		5
	Furniture and fixtures		5
	Computer equipment		3
	Impairment of Long-Lived Assets
	Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets or related asset group may not be recoverable. Determination of recoverability is based on an estimate of discounted future cash flows resulting from the use of the asset. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the asset or asset group, the carrying amount of the asset is written down to its estimated net realizable value.
	In connection with the restructuring discussed in Note 8, “Restructuring,” the Company entered into an equipment lease agreement with Buffalo BioLabs, or BBL, effective January 1, 2014 for the equipment used by the employees transitioned to BBL. The estimated fair value of those assets using a discounted cash flow approach was $243,000. Comparing this fair value to the carrying amount of the equipment as of December 31, 2013 of $536,000 resulted in a $293,000 write-down of the assets, which was included in research and development expenses for the year ended December 31, 2013.
	Restricted Cash
	Restricted cash at December 31, 2013 includes certificates of deposit denominated in Russian Rubles and posted by Panacela and BioLab 612 as collateral for performance guarantees for their contracts with the Ministry of Industry and Trade of the Russian Federation. The guarantees require Panacela and BioLab 612 to satisfactorily perform their statements of work under the contracts. Both Panacela and BioLab 612 anticipate receiving the full proceeds of their deposits at the completion of the contracts, which for each contract is more than a year away. As a consequence, all of the Company’s restricted cash is classified as a noncurrent asset.
	Intellectual Property
	Costs related to filing and pursuing patent applications are recognized as general and administrative expenses as incurred, since the recoverability of such expenditures is uncertain. Upon marketability approval by the U.S. Food and Drug Administration, or FDA, or a respective foreign governing body, such costs will be capitalized and depreciated over the expected life of the related patent.
	During the year-ended December 31, 2011, the Company performed its periodic review of capitalized patent costs and incorporated a more restrictive standard of capitalization widely utilized in the biotechnology industry, which includes a prerequisite of the FDA marketability approval as one of several factors needed to justify the continued capitalization of costs associated with securing patents. Given that the Company is currently developing requisite data towards submission to the FDA of biological license and new drug applications in support of its existing product candidates, capitalized patent costs of approximately $1,500,000 were expensed during the year ended December 31, 2011. This item has been treated as a change in estimate in the accompanying financial statements.
	Deferred Revenue
	Deferred revenue represents cash received under grants and contracts in excess of the revenue recognizable through the end of the respective financial reporting period. The revenue associated with these advances will be recognized in future periods as the applicable costs are incurred.
	Accrued Warrant Liability
	Certain warrants are accounted for as derivative instruments in accordance with the Financial Accounting Standards Board Accounting Standards Codification, or the Codification, on derivatives and hedging as the warrant holders, under certain change of control situations, could require settlement in cash. As such, the warrants were initially recorded as liabilities based on their fair values on the date of issuance. Subsequent changes in the value of the warrants are recorded in the statements of operations as “Change in value of warrant liability.”
	The Company’s remaining outstanding warrants were treated as equity upon issuance and continue to be treated as equity since they did not contain any mandatory redemption features or other provisions that would require a different classification of these warrant instruments outside of permanent equity.
	Foreign Currency Translation
	The Russian ruble is the functional currency of our foreign subsidiaries, which are all located in the Russian Federation. Assets and liabilities of these subsidiaries are translated into U.S. dollars at the period-end exchange rate. Income and expense items are translated at the average exchange rates during the period. The net effect of this translation is recorded in the consolidated financial statements as accumulated other comprehensive income (loss).
	Revenue Recognition
	The Company generates grant and contract revenue from two different types of contractual arrangements: cost reimbursable grants and contracts and fixed-price grants and contracts. Costs consist primarily of internal labor charges, subcontractors and materials, as well as an allocation of fringe benefits, overhead and general and administrative expenses, based on the terms of the contract. Under cost reimbursable grants and contracts, revenue is recognized during the period that the associated research and development costs are incurred. Under fixed-price grants and contracts, revenue is recognized using the percentage-of-completion method. The assumptions and estimates used in determination of the percentage-of-completion are developed in coordination with the principal investigator performing the work.
	Research and Development
	Research and development costs are expensed as incurred. Research and development costs primarily consist of salaries, fringe benefits, materials and related expenses for personnel and facility expenses. Other research and development expenses include fees paid to consultants and outside service providers, the costs of materials used in clinical trials and research and development and stock-based compensation.
	Accounting for Stock-Based Compensation
	The 2006 Equity Incentive Plan, as amended, or the “Plan”, authorizes CBLI to grant (i) options to purchase common stock, (ii) restricted or unrestricted stock units, and (iii) stock appreciation rights, so long as the exercise or grant price of each are at least equal to the fair market value of the stock on the date of grant. At the 2012 annual meeting of stockholders, an amendment to increase the maximum number of shares of common stock reserved for issuance under the Plan was approved, and as of December 31, 2013, an aggregate of 10.0 million shares of common stock were authorized for issuance under the Plan, of which a total of approximately 2.1 million shares of common stock remained available for future awards. A single participant cannot be awarded more than 400,000 shares annually. Awards granted under the Plan have a contractual life of no more than 10 years. The terms and conditions of equity awards (such as price, vesting schedule, term and number of shares) under the Plan are specified in an award document, and approved by compensation committee of the CBLI’s board of directors.
	The Company utilizes the Black-Scholes valuation model for estimating the fair value of all stock options granted. Set forth below are the assumptions used in valuing the stock options granted and a discussion of the Company’s methodology for developing each of the assumptions used:
		For the year ended December 31,
		2013			2012			2011
	Risk-free interest rate		.02 - 1.92	%		.65 - 1.49	%		.96 - 2.61	%
	Expected dividend yield		0	%		0	%		0	%
	Expected life		5 - 7.3 Years			5 - 6 Years			5 - 6 Years
	Expected volatility		78.62 - 89.66	%		86.58 - 92.60	%		84.28 - 92.38	%
	“Risk-free interest rate” means the range of U.S. Treasury rates with a term that most closely resembles the expected life of the option as of the date the option is granted.
	“Expected dividend yield” means the Company does not pay regular dividends on its common stock and does not anticipate paying any dividends in the foreseeable future.
	“Expected life” means the period of time that options granted are expected to remain outstanding, based wholly on the use of the simplified (safe harbor) method. The simplified method is used because the Company does not yet have adequate historical exercise information to estimate the expected life the options granted.
	“Expected volatility” means a measure of the amount by which a financial variable, such as share price, has fluctuated (historical volatility) or is expected to fluctuate (implied volatility) during a period. Expected volatility is based on the Company’s historical volatility and incorporates the volatility of the common stock of comparable companies when the expected life of the option exceeds the Company’s trading history.
	In June 2013, CBLI’s stockholders approved the 2013 Employee Stock Purchase Plan, or ESPP, which provides a means by which eligible employees of CBLI, and certain designated related corporations may be given an opportunity to purchase shares of CBLI common stock. As of December 31, 2013, there are 2.1 million shares of common stock reserved for purchase under the ESPP. The number of shares reserved for purchase under the ESPP increases on January 1 of each calendar year by the lesser of (i) 10% of the total number of shares of common stock outstanding on December 31 of the preceding year, or (ii) 200,000 shares of common stock. The ESPP allows employees to use up to 15% of their compensation to purchase shares of common stock at an amount equal to 85% of the fair market value of the our common stock on the offering date or the purchase date, whichever is less.
	Income taxes
	No income tax expense was recorded for the years ended December 31, 2013, 2012 and 2011, as the Company did not have taxable income for any of the years presented. A full valuation allowance has been recorded against the Company’s net deferred tax asset.
	Earnings/(loss) per share
	Basic net income (loss) per share of common stock excludes dilution for potential common stock issuances and is computed by dividing net income (loss) by the weighted average number of shares outstanding for the period. Diluted net income (loss) per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. Diluted net loss per share is identical to basic net loss per share as potentially dilutive securities have been excluded from the calculation of diluted net loss per common share because the inclusion of such securities would be antidilutive.
The Company has excluded the following outstanding warrants and options from the calculation of diluted net loss per share because all such securities were antidilutive for the periods presented:
	As of December 31,
Common Equivalent Securities	2013			2012			2011
Preferred Shares		—			—			—
Warrants		10,534,245			10,377,995			12,564,193
Options		5,564,833			5,016,966			4,117,979
Total		16,099,078			15,394,961			16,682,172
Comprehensive Income (Loss)
The Company applies the Codification on comprehensive income (loss) that requires disclosure of all components of comprehensive income (loss) on an annual and interim basis. Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources.
Recently Issued Accounting Pronouncements
From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.

Fair_Value_Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	3. Fair Value Measurements
	The Company measures and records cash equivalents and warrant liabilities at fair value in the accompanying financial statements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability, an exit price, in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value include:
		•		Level 1 – Observable inputs for identical assets or liabilities such as quoted prices in active markets;
		•		Level 2 – Inputs other than quoted prices in active markets that are either directly or indirectly observable; and
		•		Level 3 – Unobservable inputs in which little or no market data exists, which are therefore developed by the Company using estimates and assumptions that reflect those that a market participant would use.
	The following tables represent the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2013 and December 31, 2012:
			As of December 31, 2013
			Level 1			Level 2			Level 3		Total
	Liabilities:
	Accrued warrant liability		$	—		$	—		$	1,241,311	$	1,241,311
	Compensatory stock options not yet issued (1)			—			—			309,450		309,450
	Total liabilities		$	—		$	—		$	1,550,761	$	1,550,761
			As of December 31, 2012
			Level 1			Level 2			Level 3		Total
	Liabilities:
	Accrued warrant liability		$	—		$	—		$	4,105,659	$	4,105,659
	Total liabilities		$	—		$	—		$	4,105,659	$	4,105,659
	-1	Included in accrued expenses in the accompanying consolidated balance sheets.
	The Company has certain warrants that could require settlement in cash if a fundamental transaction occurs, as defined in the respective agreements. These agreements specify the amount due to warrant holders is based on the Black-Scholes pricing model. The following are the assumptions used to measure the accrued warrant liability at December 31, 2013 and 2012, which were determined in a manner consistent with that described for grants of options to purchase common stock as set forth in Note 2, “Summary of Significant Accounting Policies”:
			December 31, 2013			December 31, 2012
	Stock Price		$	1.17		$	1.33
	Exercise Price		$	1.60 - 5.00		$	1.60 - 5.00
	Term in years			0.59 - 1.91			1.09 - 2.41
	Volatility			42.52 - 76.03	%		82.75 - 95.91	%
	Annual rate of quarterly dividends			0	%		0	%
	Discount rate- bond equivalent yield			.08 - .36	%		.17 - .29	%
	The following are the assumptions used to measure the compensatory stock options not yet issued at December 31, 2013:
			December 31, 2013
	Stock price		$	0.72
	Term in years			5
	Volatility			75.68	%
	Annual rate of quarterly dividends			0	%
	Discount rate – bond equivalent yield			1.52	%
	The following table sets forth a summary of changes in the fair value of the Company’s Level 3 fair value measurements for the year ended December 31, 2013 and 2012:
			Year Ended December 31, 2013
			Accrued Warrant			Compensatory
			Liability			Stock Options
						Issued After Year
						End
	Beginning Balance		$	4,105,659		$	—
	Total (gains) or losses, realized and unrealized, included in earnings (1)(2)			(2,864,348	)		—
	Estimates and other changes in fair value			—			309,450
	Balance, December 31, 2013		$	1,241,311		$	309,450
			Year Ended December 31, 2012
			Accrued Warrant			Compensatory
			Liability			Stock Options
						Issued After Year
						End
	Beginning Balance		$	7,285,959		$	378,750
	Total (gains) or losses, realized and unrealized, included in earnings (1)(2)			(7,701,981	)		51,823
	Issuances			4,521,681			—
	Settlements			—			(430,573	)
	Balance, December 31, 2012		$	4,105,659		$	—
	-1	Unrealized gains or losses related to the accrued warrant liability were included as change in value of accrued warrant liability. There were no realized gains or losses for the years ended December 31, 2013 and 2012.
	-2	Expenses recorded for compensatory stock options not yet issued are included in research and development expense and general and administrative expense.
	Separate disclosure is required for assets and liabilities measured at fair value on a recurring basis, as documented above, from those measured at fair value on a nonrecurring basis. As of December 31, 2013 and 2012, the Company had no assets or liabilities that were measured at fair value on a nonrecurring basis.
	The Company considers the accrued warrant liability and compensatory stock options not yet issued to be Level 3 because some of the inputs into the measurements are neither directly or indirectly observable. Both the accrued warrant liability and compensatory stock options not yet issued use management’s estimate for the expected term, which is based on the safe harbor method as historical exercise information over the term of each security is not readily available. Additionally, the number of compensatory options awarded involves an estimate of management’s performance in relation to the targets set forth in the Company’s annual Executive Compensation Plan. The following table summarizes the unobservable inputs into the fair value measurements:
			December 31, 2013
	Description		Fair Value			Valuation Technique		Unobservable Input	Range
	Compensatory stock options not yet issued		$	309,450		Black-scholes pricing model		Expected term		5
								Quantity of options		696,000
	Accrued warrant liability			1,241,311		Black-scholes pricing model		Expected term		0.59 - 1.91
			$	1,550,761
Management believes the value of the accrued warrant liability and compensatory stock options are more sensitive to changes in the Company’s stock price at the end of the respective reporting period as opposed to changes in the expected term. At December 31, 2013, a 10% increase in the expected term of the Company’s warrants measured using the Black-Scholes pricing model would increase the warrant liability by approximately 22%, while a 10% decrease in the expected term would decrease the warrant liability by approximately 16%. A 10% increase in the Company’s stock price would result in an increase in the accrued warrant liability of approximately 32%, while a 10% decrease in the stock price would decrease the warrant liability by approximately 26%. At December 31, 2013, a 10% increase or decrease in the expected term of the Company’s compensatory stock options not yet issued would increase or decrease the amount accrued by approximately 6%, while a 10% increase or decrease in the stock price would increase or decrease the amount accrued by approximately 10%.
The carrying amounts of the Company’s remaining financial instruments, which include cash, short-term investments, accounts receivable and accounts payable, approximate their fair values due to their short maturities.

Equipment

Equipment	12 Months Ended
	Dec. 31, 2013
Property Plant And Equipment [Abstract]	'
Equipment	'
	4. Equipment
	The following table summarizes the Company’s gross equipment costs for the years ended December 31, 2013 and 2012:
		As of December 31,
		2013			2012
	Lab equipment	$	1,083,463		$	1,903,533
	Computer equipment		332,386			335,264
	Furniture		528,807			523,665
			1,944,656			2,762,462
	Less accumulated depreciation		(1,486,744	)		(1,775,909	)
	Equipment, net	$	457,912		$	986,553

Noncontrolling_Interests

Noncontrolling Interests	12 Months Ended
	Dec. 31, 2013
Noncontrolling Interest [Abstract]	'
Noncontrolling Interests	'
	5. Noncontrolling Interests
	On May 31, 2012, Bioprocess Capital Partners, LLC, or BCP, the noncontrolling interest holder in Incuron, contributed approximately 194.0 million Russian rubles (approximately $5.9 million) to Incuron, which increased its ownership percentage to 40.8% and decreased CBLI’s ownership percentage to 59.2%, which is the ownership percentage at December 31, 2013.
	On January 20, 2011 and March 14, 2011, BCP contributed 68.0 million Russian Rubles (approximately $2.3 million) and 1.73 million Russian Rubles (approximately $0.1 million), respectively, to Incuron, increasing their ownership percentage from 16.1% to 24.2% and decreasing CBLI’s ownership percentage from 83.9% to 75.8%.
	The following quantifies the effects of changes in CBLI’s ownership interest in Incuron, on CBLI’s equity for the years ending December 31, 2013, 2012 and 2011:
		For the Year Ending December 31,
		2013			2012			2011
	Net loss attributable to CBLI	$	(17,262,877	)	$	(18,234,142	)	$	(4,013,670	)
	Increase in CBLI’s additional paid-in capital due to the issuance of additional membership interests to the noncontrolling interest of Incuron		—			1,081,040			176,092
	Change from net income attributable to CBLI and issuance of additional membership interests to the noncontrolling interest of Incuron	$	(17,262,877	)	$	(17,153,102	)	$	(3,837,578	)
	On October 4, 2011, CBLI consummated the transactions contemplated by the Investment Agreement, dated as of September 19, 2011, or the Investment Agreement, with Open Joint Stock Company “Rusnano”, or Rusnano, to provide funding to Panacela to carry out a complete cycle of development, research, performance of clinical trials, production and sales of a line of pharmaceutical drugs for the treatment of oncological, infectious or other diseases.
	Pursuant to the Investment Agreement, (i) CBLI invested $3.0 million in Panacela preferred shares and warrants, and, together with certain third-party owners, assigned and/or provided exclusive licenses, as applicable, to Panacela in respect of certain intellectual property in exchange for Panacela common shares, and (ii) Rusnano invested $9.0 million in Panacela preferred shares and warrants, with an additional $17.0 million available for investment. $1.5 million of the $17.0 million was invested in the form of a convertible loan, discussed in Note 6, “Debt,” leaving $15.5 million currently available to be invested at Rusnano’s option. At December 31, 2013, CBLI had an ownership stake of 54.6% in Panacela.
	The Panacela preferred shares are convertible into common shares at any time following issuance. The conversion price is equal to the preferred share issuance price of $1,057 per share, subject to proportional adjustment for any stock split, stock dividend, reclassification or similar event with respect to the Panacela common shares. The preferred shares are automatically convertible into common shares upon the occurrence of a qualifying public offering of Panacela, carry no redemption rights and have the ability to vote and participate in dividends on a basis consistent with common shareholders.
	The Panacela warrants provide CBLI and Rusnano with an option to increase their respective investments at two and four years following the initial investment. The warrants are exercisable into Panacela preferred shares at an exercise price equal to 20% or 40% above the preferred stock issuance price of $1,057 per share, subject to proportional adjustment for any stock split, stock dividend, reclassification or similar event with respect to the Panacela common shares. The warrants issued to CBLI and Rusnano that had an exercise price equal to 20% above the preferred stock issuance price expired in October 2013.
	The preferred shares and warrant instruments have been classified as permanent equity instruments by Panacela. The value assigned to the preferred shares and warrants was based on their relative fair value at the date of issuance. The resultant embedded beneficial conversion feature relating to the preferred shares was considered a deemed dividend, and since Panacela had an accumulated deficit, had no impact on the Panacela statement of stockholders’ equity.

Debt

Debt	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Debt	'
	6. Debt
	On September 30, 2013, CBLI and BioLab 612 entered into a Loan and Security Agreement, or the Loan Agreement, with Hercules Technology II, L.P., or Hercules, pursuant to which we issued a $6 million note and received net proceeds of $5.9 million. The loan bears interest at the greater of (i) 10.45% per annum or (ii) 10.45% plus the prevailing prime rate minus 4.25%. The loan matures on January 1, 2017, and requires interest-only payments for the initial 12 months and principal and interest payments in 27 monthly installments thereafter.
	In connection with the Loan Agreement, CBLI granted a first priority lien in substantially all of CBLI’s assets (exclusive of intellectual property). The Loan Agreement also contains representations and warranties by CBLI and Hercules, indemnification provisions in favor of Hercules, customary covenants (including limitations on other indebtedness, liens, acquisitions, investments and dividends, but excluding any financial covenants), and events of default (including payment defaults, breaches of covenants, material adverse events and events leading to bankruptcy or insolvency). Prepayment of the loan is subject to a penalty rate applied to the balance of the secured obligation and ranges from 1% to 3% based on the date the loan is prepaid. Additionally, Hercules has a right to participate in subsequent private placements of CBLI equity securities at the same price, terms and conditions as other investors, up to an aggregate amount of $1 million.
	As additional consideration for the loan, CBLI issued Hercules a five-year warrant to purchase 156,250 shares of CBLI common stock at an exercise price of $1.60 per share. The Company recorded the fair value of the warrant of $117,999 as equity and as a discount to the carrying value of the loan. The fair value of the warrant was calculated using the Black-Scholes option pricing model with the following assumptions:
	Risk-free interest rate		0.48	%
	Expected dividend yield		0	%
	Expected life (years)		2.5
	Expected volatility		82.29	%
	Reflected as a discount to the loan are the following items: the warrant, a $100,000 facility fee CBLI paid to Hercules which was deducted from the gross proceeds of the loan, and a $550,000 payment that is due upon full repayment of the loan or on the maturity date, whichever occurs sooner. In connection with the closing of the loan, CBLI incurred $102,000 in debt issuance costs, primarily related to legal fees, which are included in non-current assets in our consolidated balance sheet. CBLI will amortize the loan discounts and debt issuance costs to interest expense over the term of the loan using the effective interest rate method, which approximates 16.6%. Additionally, the $550,000 end-of-term charge is also reflected as a long-term liability in conjunction with the $6 million note.
	The Loan Agreement triggered a reduction in the exercise price of the Company’s warrants issued in March 2010 from $2.00 to $1.60 per share.
	The following schedule shows the payments for principal and the end of term charge on the Hercules loan by calendar year:
	2014	$	351,527
	2015		2,246,215
	2016		2,495,163
	2017		1,457,095
	Total	$	6,550,000
	On September 3, 2013, Panacela entered into a Master Agreement, or the Panacela Loan, with Rusnano and CBLI pursuant to which Panacela issued a $1,530,000 note to Rusnano. The Panacela Loan bears interest at a rate of 16.3% per annum and matures on September 10, 2015, at which time Panacela must repay all unpaid principal and accrued interest. Prior to March 10, 2015, the loan is mandatorily convertible into shares of Panacela preferred stock at a conversion price of $1,057 per share if Panacela completes a qualified financing in accordance with the terms of the Panacela Loan. Subsequent to March 10, 2015, Rusnano has the option to convert the unpaid principal plus interest into shares of Panacela preferred stock at a conversion price of $1,057 per share, or if Panacela has a qualified financing event, at a discounted price of 0.75 times the purchase price per share.
	In connection with the Panacela Loan, CBLI issued Rusnano a warrant that has an exercise period that begins upon an event of default on the Panacela Loan and expires on December 31, 2016. Upon an event of default, Rusnano has the option to assign 69.2% of the unpaid principal and interest under the Panacela Loan to CBLI in exchange for shares of CBLI common stock at a price of $1.694 per share.
	For the year ended December 31, 2013, included in interest and other income (expense) are $256,970 and $81,142 of interest expense related to the Hercules Loan Agreement and Panacela Loan, respectively.

Stockholders_Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
Stockholders' Equity	'
	7. Stockholders’ Equity
	In October 2012, CBLI completed a public offering of 7,500,000 units at a price of $2.00 per unit, with each unit consisting of one share of CBLI common stock, par value $0.005 per share, and one warrant to purchase 0.5 of a share of CBLI common stock at an exercise price of $3.00 per whole share, or the 2012 Offering. The shares of CBLI common stock and the warrants issued in the 2012 Offering were issued separately. Under the terms of the related underwriting agreement, CBLI granted the Underwriters an option, exercisable for 30 days, to purchase up to an additional 1,125,000 shares of CBLI common stock (with an over-allotment price of $1.995 per share) and/or additional warrants to purchase up to 562,500 shares of CBLI common stock (with an over-allotment price of $0.0094 for each warrant to purchase a whole share) to cover over-allotments, if any. The underwriter exercised their option in part by purchasing 1,025,000 shares and 562,500 warrants of the over-allotment option within 30 days of the closing.
	Certain warrants issued during the 2012 offering contain provisions that could require the Company to settle the warrants in cash and, accordingly, were originally recorded as a liability in the amount of $4,521,681 determined by the Black-Scholes valuation model with the following assumptions:
	Stock price	$	2.48
	Exercise price	$	3
	Term in years		2.51
	Volatility		79.7	%
	Annual rate of quarterly dividends		—
	Discount rate- bond equivalent yield		0.35	%
	The 2012 Offering triggered a reduction in the exercise price of the Company’s warrants issued in March 2010 from $4.00 to $2.00 per share.
	In June 2011, the Company issued 5,872,500 shares of its common stock and warrants to purchase a total of 2,936,250 shares of its common stock for gross proceeds of $23.5 million. The common stock and warrants were sold in units, at a price of $4.00 per unit, with each unit consisting of: (i) one share of common stock; (ii) a warrant to purchase 0.25 of a share of common stock, with an exercise price of $4.50 per share; and (iii) a warrant to purchase 0.25 of a share of common stock, with an exercise price of $5.00 per share. In addition, the placement agent and the financial advisor also collectively received warrants to purchase up to 176,175 shares of common stock. In the event of stock splits, stock dividends, combinations of shares and similar recapitalization transactions, the number of shares issuable and the exercise price associated with all warrants issued in this transaction may be adjusted. At December 31, 2011, all outstanding warrants were exercisable.
	Certain warrants issued in June 2011 contain provisions that could require the Company to settle the warrants in cash, and accordingly, were originally recorded as a liability in the amount of $2,525,175 determined by the Black-Scholes valuation model with the following assumptions:
	Stock price	$	4.45
	Exercise price	$	5
	Term in years		2.5
	Volatility		69.36	%
	Annual rate of quarterly dividends		—
	Discount rate- bond equivalent yield		0.53	%
	The following table sets forth the changes in the number of warrants outstanding for the periods presented, exclusive of the warrants issued to Rusnano in connection with their loan to Panacela as those warrants are not exercisable until an event of default which has not occurred:
		Number of			Weighted Average		Number of Common
		Warrants			Exercise Price		Shares Exercisable Into
	Outstanding at December 31, 2011		10,121,219		$	3.76		12,564,193
	Granted		4,312,500			3		4,312,500
	Forfeited, Canceled		(4,055,724	)		5.07		(6,498,698	)
	Outstanding at December 31, 2012		10,377,995			2.94		10,377,995
	Granted		156,250			1.6		156,250
	Outstanding at December 31, 2013		10,534,245			2.7		10,534,245
	The following table sets forth the details of the outstanding warrants as of December 31, 2013:
	Expiration Date	Current			Number of
		Exercise Price			Warrants
	March 2, 2015	$	1.6			935,385
	June 17, 2015		5			176,175
	February 12, 2016		1.6			929,826
	March 19, 2016		1.6			1,921,795
	March 26, 2016		1.6			634,189
	June 22, 2016		5			1,468,125
	October 24, 2017		3			4,312,500
	September 30, 2018		1.6			156,250
						10,534,245
	The January 2014 equity offering, as described in Note 14, “Subsequent Events”, triggered a reduction in the exercise price of certain warrants. All warrants in the table above that have an exercise price of $1.60 now have an exercise price of $1.22, except for the 156,250 warrants that expire on September 30, 2018.
	Equity Incentive Plan
	The following is a summary of option award activity under the Plan for the year ended December 31, 2013:
		Year Ended December 31, 2013
		Total Stock Options			Weighted Average		Nonvested Stock			Weighted Average
		Outstanding			Exercise Price per		Options			Grant Date Fair
					Share					Value per Share
	December 31, 2012		5,016,916		$	4.54		404,500		$	2.3
	Granted		903,775			1.67		903,775			1.21
	Vested		—			—		(513,296	)		1.73
	Exercised		(9,681	)		1.28		—			—
	Forfeited, Canceled		(346,177	)		3.53		(200,500	)		1.21
	December 31, 2013		5,564,833			4.14		594,479			1.5
	The following is a summary of outstanding stock options under the Plan as of December 31, 2013:
		Stock Options			Vested Stock
		Outstanding			Options
	Quantity		5,564,833			4,970,354
	Weighted-average exercise price	$	4.14		$	4.4
	Weighted Average Remaining Contractual Term (in Years)		6.75			6.47
	Intrinsic value	$	11,592		$	11,592
	For the years ended December 31, 2013, 2012 and 2011, the Company granted 903,775, 1,132,383, and 1,459,393 stock options, respectively, with a weighted-average grant date fair value of $1.21, $1.32 and $4.04, respectively. For the years ended December 31, 2013, 2012 and 2011, the total fair value of options vested was $887,603, $1,549,888 and $5,381,855, respectively. The total intrinsic value of options exercised for the years ended December 31, 2013, 2012 and 2011 was $5,736, $1,485 and $818,723, respectively.
	As of December 31, 2013, total compensation cost not yet recognized related to non-vested stock options was $445,647. The Company expects to recognize this cost over a weighted average period of 0.76 years.

Restructuring

Restructuring	12 Months Ended
	Dec. 31, 2013
Restructuring And Related Activities [Abstract]	'
Restructuring	'
	8. Restructuring
	On September 30, 2013, we transferred 26 laboratory and pre-clinical employee positions to BBL, an entity owned in part by our Chief Scientific Officer and director, Dr. Andrei Gudkov, to enable us to better focus on clinical development activities. In connection with this transition, we entered into a Master Services Agreement, or MSA, with BBL, pursuant to which BBL agreed to perform laboratory and pre-clinical research services for us. We plan to engage BBL for pre-clinical research services in the future. Such services are discussed further in Note 9, “Significant Alliances and Related Parties.”
	As a result of the above described restructuring, we recorded $101,000 for one-time employee transition costs, $112,000 for an idle facilities reserve and $293,000 for an impairment loss on research equipment. All of these costs were recorded as R&D expense during the year ended December 31, 2013. As of December 31, 2013, an accrual of $100,000 related to these restructuring costs was included in accrued expenses.

Significant_Alliances_and_Rela

Significant Alliances and Related Parties	12 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
Significant Alliances and Related Parties	'
	9. Significant Alliances and Related Parties
	Roswell Park Cancer Institute
	The Company has entered into several agreements with Roswell Park Cancer Institute, or RPCI, including: various sponsored research agreements, an exclusive license agreement and clinical trial agreements for the conduct of the Phase 1 Entolimod oncology study and the Phase 1 CBL0137 intravenous administration study. Additionally, the Company’s Chief Scientific Officer is the Senior Vice President of Basic Research at RPCI.
	The Company recognized $0, $0 and $2,317,218 of revenue from RPCI during the years ended December 31, 2013, 2012 and 2011, respectively. The Company incurred $2,323,078, $3,876,073 and $2,689,503 in expense to RPCI related to research grants and agreements for the years ended December 31, 2013, 2012 and 2011, respectively. The Company had $172,295 and $900,300 included in accounts payable owed to RPCI at December 31, 2013 and 2012, respectively. In addition, the Company had $491,397 and $553,644 in accrued expenses payable to RPCI at December 31, 2013 and 2012, respectively.
	Cleveland Clinic Foundation
	CBLI has entered into an exclusive license agreement, or the License, with the Cleveland Clinic Foundation, or CCF, pursuant to which CBLI was granted an exclusive license to CCF’s research base underlying our therapeutic platform and certain product candidate in development by Panacela. CBLI has the primary responsibility to fund all newly developed patents; however, CCF retains ownership of those patents covered by the agreement. CBLI also has agreed to use commercially diligent efforts to bring one or more products to market as soon as practical, consistent with sound and reasonable business practices and judgments. In consideration for the CCF License, CBLI agreed to issue CCF common stock and make certain milestone, royalty and sublicense royalty payments. Milestone payments, which may be credited against future royalties, amounted to $0, $100,000 and $100,000 for the years ended December 31, 2013, 2012 and 2011, respectively. No royalty or sublicense royalty payments were made to CCF in the years ended December 31, 2013, 2012 and 2011, respectively.
	The Company also recognized $7,516, $4,804 and $2,558 as research and development expense to CCF for the years ended December 31, 2013, 2012 and 2011, respectively. The Company did not have any liabilities to CCF at December 31, 2013 and 2012.
	Consultants
	CBLI has entered into a consulting agreement with our Chief Scientific Officer, Dr. Andrei Gudkov. The Company incurred $202,843, $200,695 and $186,224 for consulting services in the years ending December 31, 2013, 2012 and 2011, respectively. The Company incurred $0, $0 and $24,476 in bonuses for the years ending December 31, 2013, 2012 and 2011, respectively. The Company incurred $164,661, $32,659 and $109,137 in non-cash, stock based compensation expense for the years ending December 31, 2013, 2012 and 2011, respectively.
	The Company had $62,059 and $28,245 for consulting services included in accrued expenses at December 31, 2013 and 2012, respectively. The Company had $66,692 and $24,476 included in accrued bonuses at December 31, 2013 and 2012, respectively.
	Dr. Gudkov has equity interests in other entities, not including BBL, that are unaffiliated with the Company. The Company recognized $29,607, $0 and $0 as research and development expense to these entities for the years ended December 31, 2013, 2012 and 2011, respectively. As of December 31, 2013 and 2012, there were no amounts owed to these entities. During the years ended December 31, 2013 and 2012, the Company recognized other income from these entities of $217,347 and $407,395, respectively. The Company held no accounts receivable from these entities as of December 31, 2013 and 2012.
	Buffalo BioLabs
	Pursuant to the MSA that was executed with BBL (see Note 8, “Restructuring”), the Company recognized $419,284 as research and development expense for the year ended December 31, 2013, and included $111,356 in accounts payable at December 31, 2013. We also received $64,362 and $6,500 from BBL for sublease and other income for the years ended December 31, 2013 and 2012, respectively.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	10. Income Taxes
	The Company accounts for income taxes using the asset and liability method. Deferred taxes are determined by calculating the future tax consequences attributable to differences between the financial accounting and tax bases of existing assets and liabilities. A valuation allowance is recorded against deferred tax assets when, in the opinion of management, it is more likely than not that the Company will not be able to realize the benefit from its deferred tax assets.
	The Company files income tax returns, as prescribed by the national, state and local jurisdictions in which it operates. The Company’s uncertain tax positions are related to tax years that remain subject to examination and are recognized in the financial statements when the recognition threshold and measurement attributes are met. Interest and penalties related to tax deficiencies and uncertain tax positions are recorded as income tax expense.
	Income (loss) from continuing operations consists of the following:
		For the Year Ended December 31,
		2013			2012			2011
	US operations	$	(13,505,266	)	$	(14,317,608	)	$	(1,775,053	)
	Foreign operations		(6,624,018	)		(8,097,032	)		(3,454,672	)
		$	(20,129,284	)	$	(22,414,640	)	$	(5,229,725	)
	The provision for income taxes charged to continuing operations is $0 for all periods presented.
	Deferred tax assets (liabilities) were comprised of the following as of the periods presented below:
		As of December 31,
		2013			2012			2011
	Deferred tax assets:
	Operating loss carryforwards	$	44,120,000		$	37,642,000		$	28,972,000
	Accrued expenses		8,861,000			8,576,000			7,778,000
	Tax credit carryforwards		3,186,000			2,921,000			2,537,000
	Intellectual property		4,846,000			3,377,000			1,604,000
	Outside tax basis difference in affiliate		2,825,000			1,616,000			1,378,000
	Equipment		388,000			237,000			156,000
	Other		—			4,000			4,000
	Total deferred tax assets		64,226,000			54,373,000			42,429,000
	Deferred tax liabilities		—			—			—
	Net deferred tax asset		64,226,000			54,373,000			42,429,000
	Valuation allowance		(64,226,000	)		(54,373,000	)		(42,429,000	)
		$	—		$	—		$	—
	The provision for income taxes differs from the amount of income tax determined by applying the applicable U.S. statutory federal income tax rate to the pretax loss from continuing operations as a result of the following differences:
		For the Year Ended December 31,
		2013			2012			2011
	Tax at the U.S. statutory rate	$	(6,810,000	)	$	(7,621,000	)	$	(1,778,000	)
	Change in value of warrant liability		(974,000	)		(2,619,000	)		(6,739,000	)
	Stock option expenses		—			—			(140,000	)
	Valuation allowance		7,723,000			10,204,000			8,639,000
	Other		61,000			36,000			18,000
		$	—		$	—		$	—
	At December 31, 2013, the Company has U.S. federal net operating loss carryforwards of approximately $109,919,000, which begin to expire if not utilized by 2023, and approximately $3,313,000 of tax credit carryforwards that begin to expire if not utilized by 2024. The Company also has U.S. state net operating loss carryforwards of approximately $99,930,000, which begin to expire if not utilized by 2027 and state tax credit carryforwards of approximately $318,000, which begin to expire if not utilized by 2022.
	The Company files U.S. federal tax returns, along with various state and foreign income tax returns. All federal, state and foreign tax returns for the years ended December 31, 2012, 2011 and 2010 are still open for examination.
	The following presents a roll-forward of the unrecognized tax benefits and the associated interest and penalties:
		Unrecognized			Interest
		Tax Benefits			and Penalties
	Balance at January 1, 2012	$	407,000		$	—
	Prior year tax position		—			—
	Current year tax position		—			—
	Deferred tax position		30,000			—
	Settlements with tax authorities		—			—
	Expiration of the statute of limitations		—			—
	Balance at December 31, 2012		437,000			—
	Prior year tax position		—			—
	Current year tax position		—			—
	Deferred tax position		8,000			—
	Settlements with tax authorities		—			—
	Expiration of the statute of limitations		—			—
	Balance at December 31, 2013	$	445,000		$	—
	CBLI received New York State incentive tax credit refunds of $62,000, $532,000 and $367,000 during 2013, 2012 and 2011, respectively. These refundable tax credits were based on the Company’s research and development activities, real estate tax payments, employment levels and equipment purchases. Since there is no state tax liability or refund of prior year tax payments, these refundable tax credits were recorded against operating expenses in the year of receipt, instead of being recorded as an income tax benefit.

Employee_Benefit_Plan

Employee Benefit Plan	12 Months Ended
	Dec. 31, 2013
Compensation And Retirement Disclosure [Abstract]	'
Employee Benefit Plan	'
	11. Employee Benefit Plan
	CBLI maintains an active defined contribution retirement plan for its employees, referred to herein as the Benefit Plan. All employees satisfying certain service requirements are eligible to participate in the Benefit Plan. The Company makes matching cash contributions each payroll period, up to 4% of employees’ contributions. The Company’s expense relating to the Benefit Plan was $196,257, $201,510 and $182,669 for the years ended December 31, 2013, 2012 and 2011, respectively.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments And Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	12. Commitments and Contingencies
	The Company has entered into various agreements with third parties and certain related parties in connection with the research and development activities of its existing product candidates as well as discovery efforts on potential new product candidates. These agreements include fixed obligations to sponsor research and development activities and minimum royalty payments for licensed patents. These amounts do not include any additional amounts that the Company may be required to pay under its license agreements upon the achievement of scientific, regulatory and commercial milestones, including milestones such as the submission of an IND to the FDA and the first commercial sale of the Company’s products in various countries. As of December 31, 2013 the Company is uncertain as to whether any of these contingent events will become realized. The Company is also party to five agreements that require it to make milestone payments, pay royalties on net sales of the Company’s products, and make payments on sublicense income received by the Company relating to certain products. There were no milestone payments or royalties on net sales accrued for any of these agreements as of December 31, 2013 and 2012 as none were due.
	From time-to-time, the Company may have certain contingent liabilities that arise in the ordinary course of business. The Company accrues for liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. For all periods presented, the Company is not a party to any pending material litigation or other material legal proceedings.
	The Company has entered into agreements with three key executives who, if terminated by the Company without cause as described in these agreements, would be entitled to severance pay.
	As of December 31, 2013, the Company had unconditional purchase obligations totaling $1,024,477 for goods and services, all of which the Company anticipates to incur during 2014.
	Capital Lease
	In December 2011, the Company entered into a capital lease for scientific equipment in the amount of $304,673. The terms of the lease required an upfront payment of $82,983 and monthly payments of $7,616 for 36 months once the lease term began in March 2012. Principal payments under the capital lease obligation were $78,125 and $52,410 for the years ended December 31, 2013 and 2012, respectively. Interest payments under the capital lease obligation were $20,827 and $23,708 for the years ended December 31, 2013 and 2012, respectively. As of December 31, 2012, accumulated depreciation for the leased equipment was $50,779. As of December 31, 2013, the Company recognized an impairment loss of $105,491 related to this leased asset as the anticipated discounted future cash flows resulting from the lease with BBL exceeded the carrying value of the asset, and as such, the Company adjusted the gross cost and carrying value down to $87,468, resulting in $0 accumulated depreciation as of December 31, 2013.
	As of December 31, 2013, future minimum future lease payments under capital leases are as follows:
	2014	$	91,341
	2015		7,612
	Total minimum lease payments		98,953
	Interest expense related to future periods		7,797
	Present value of minimum lease payments		91,156
	Less: current portion		83,634
	Non-current portion	$	7,522
	Operating Leases
	The Company leases laboratory facilities and office facilities at various locations with expiration dates ranging from 2014 to 2019. The Company recognizes rent expense on a straight-line basis over the term of the related operating leases. For the years ended December 31, 2013, 2012 and 2011, total rent expense related to the Company’s operating leases was $511,029, $459,150 and $396,667, respectively.
	As of December 31, 2013, future minimum payments under operating leases are as follows:
	2014	$	471,925
	2015		344,580
	2016		354,918
	2017		365,565
	2018		376,532
	2019		191,048
	Total minimum lease payments	$	2,104,568

Quarterly_Financial_Data_Unaud

Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Quarterly Financial Data (Unaudited)	'
	13. Quarterly Financial Data (Unaudited)
	The following is a summary of the quarterly consolidated results of operations for the years ended December 31, 2013 and December 31, 2012:
		For the Quarter Ended
		March 31, 2013			June 30, 2013			September 30, 2013			December 31, 2013
	Revenues	$	1,367,472		$	1,613,262		$	1,635,600		$	3,871,632
	Loss from Operations		(7,447,515	)		(6,776,618	)		(5,856,468	)		(2,996,158	)
	Net Income (Loss)		(10,787,148	)		(3,886,421	)		(4,610,961	)		(844,754	)
	Net Income (Loss) Attributable to Cleveland BioLabs, Inc.		(9,764,323	)		(3,042,111	)		(4,091,196	)		(365,247	)
	Basic Earnings (Loss) Per Share Available for Common Shareholders	$	(0.22	)	$	(0.07	)	$	(0.09	)	$	(0.01	)
	Fully Diluted Earnings (Loss) Per Share Available for Common Shareholders	$	(0.22	)	$	(0.07	)	$	(0.09	)	$	(0.01	)
	Weighted Average Shares Outstanding, Basic		44,826,576			44,948,591			45,061,274			45,170,129
	Weighted Average Shares Outstanding, Diluted		44,826,576			44,948,591			45,061,274			45,170,129
		For the Quarter Ended
		March 31, 2012			30-Jun-12			September 30, 2012			December 31, 2012
	Revenues	$	931,397		$	258,237		$	219,575		$	2,161,501
	Loss from Operations		(7,481,875	)		(9,161,724	)		(7,841,541	)		(5,561,466	)
	Net Income (Loss)		(6,398,894	)		(5,906,870	)		(12,315,676	)		2,206,800
	Net Income (Loss) Attributable to Cleveland BioLabs, Inc.		(5,387,146	)		(5,078,684	)		(10,877,836	)		3,109,524
	Basic Earnings (Loss) Per Share Available for Common Shareholders	$	(0.15	)	$	(0.14	)	$	(0.30	)	$	0.07
	Fully Diluted Earnings (Loss) Per Share Available for Common Shareholders	$	(0.15	)	$	(0.14	)	$	(0.30	)	$	0.07
	Weighted Average Shares Outstanding, Basic		35,657,563			35,745,675			35,879,245			42,236,226
	Weighted Average Shares Outstanding, Diluted		35,657,563			35,745,675			35,879,245			42,565,945

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
Subsequent Events	'
	14. Subsequent Events
	On January 16, 2014, the Company completed a public offering of 5,737,706 shares of the Company’s common stock at a price of $1.22 per share, resulting in net proceeds of approximately $6.4 million after deducting for placement agent fees and offering expenses. In connection with the offering, the Company issued 2,868,853 Series A Warrants and 2,868,853 Series B Warrants to the purchasers. Each Series A Warrant has an exercise price of $1.22 per share, and will become exercisable six months following the date of issuance and expire five years from the date of issuance. Each Series B Warrant has an exercise price of $1.22 per share, and will become exercisable six months following the date of issuance and expire 18 months from the date of issuance. In addition to the warrants issued to the purchasers, the Company also issued 86,066 of Series A Warrants and 86,066 of Series B Warrants to the placement agent as compensation for completing the offering. The warrants to the placement agent have the same terms, including exercise price, as the warrants issued to investors. The offering also triggered a reduction in the exercise price of 4,421,195 of the Company’s warrants from $1.60 to $1.22.
	On February 20, 2014, Sabby Healthcare Volatility Master Fund, Ltd. and Sabby Volatility Warrant Master Fund, Ltd., two purchasers in the January 2014 sale of securities, brought suit in the U.S. District Court for the Southern District of New York against the Company in an action captioned Sabby Healthcare Volatility Master Fund, Ltd. v. Cleveland Biolabs, Inc., No. 14-cv-1055 (S.D.N.Y.). The plaintiffs allege that the Company misrepresented the state of its funding negotiations with BARDA during the period leading up to the sale of the Securities, and as a result, the plaintiffs were harmed when the Company’s stock price declined following the announcement that BARDA had terminated negotiations with the Company. The complaint asserts claims under Section 10(b) of the Securities Exchange Act of 1934 and SEC Rule 10b-5, as well as claims for fraudulent inducement, breach of contract, and indemnification. The plaintiffs seek $2 million, plus interest, attorney’s fees, and litigation costs.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Basis of Presentation and Consolidation	'
	Basis of Presentation and Consolidation
	The accompanying consolidated financial statements include the accounts of CBLI and its subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. These financial statements have been prepared on the accrual basis in accordance with accounting principles generally accepted in the United States, or GAAP.
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	Of the $10 million and $25.7 million of cash and cash equivalents at December 31, 2013 and December 31, 2012, respectively, $3.5 million and $13.0 million, respectively, consisted of highly liquid investments with maturities of 90 days or less when purchased. These investments consist of commercial paper, short-term debt securities, time deposits and investments in money market funds with commercial banks and financial institutions. As of December 31, 2013, $2.0 million of the Company’s cash and cash equivalents were restricted to the use of its majority-owned subsidiaries, leaving $8.0 million available for general use.
Short-Term Investments	'
	Short-Term Investments
	The Company’s short-term investments are classified as held to maturity given the intent and ability to hold the investments to maturity. Accordingly, these investments are carried at amortized cost. Short-term investments classified as held-to-maturity consisted of certificates of deposit with maturity dates beyond three months and less than one year. As of December 31, 2013, all of the Company’s short-term investments were restricted for use by its majority-owned subsidiaries.
Concentrations of Credit Risk	'
	Concentrations of Credit Risk
	Financial instruments that potentially subject the Company to a significant concentration of credit risk primarily consist of cash and cash equivalents and short-term investments. The Company maintains cash balances with financial institutions in excess of insured limits. The Company does not believe it is exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.
	As of December 31, 2013, the Company held 36% of its cash and cash equivalents and 100% of its short-term investments in accounts located outside of the United States.
	As of March 11, 2014, the Russian Ruble exchange rate increased from $32.2792 to $36.2618, resulting in a decrease of $350,557 to the Company’s cash and cash equivalents and $29,765 to the Company’s short-term investment balances as compared to December 31, 2013.
Significant Customers and Accounts Receivable	'
	Significant Customers and Accounts Receivable
	Grant and contract revenue from the United States government accounted for 26.8%, 34.8% and 87.6% of total revenue for the years ended December 31, 2013, 2012 and 2011, respectively. The Company anticipates that its sources of revenue in the near future will be from development contracts from the United States and Russian federal governments, however there is no guarantee that this revenue stream will continue in the future.
	Grant and contract revenue received by our subsidiaries from Russian government agencies accounted for 73.2%, 65.2% and 12.4% of total revenues for the years ended December 31, 2013, 2012 and 2011, respectively.
	Accounts receivable consist of amounts due under contracts with certain government and foreign entities. The Company extends unsecured credit to its government customers under normal trade agreements and contracted terms, which generally require payment within 30 days.
	Management estimates an allowance for doubtful accounts that is based upon management’s review of delinquent accounts and an assessment of the Company’s historical evidence of collections. There were no allowances for doubtful accounts as of December 31, 2013 and 2012, as the collection history from the Company’s customers indicated that collection was probable.
Equipment	'
	Equipment
	Equipment is stated at cost, net of accumulated depreciation. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repair and maintenance costs are expensed as incurred.
	Equipment is depreciated using the straight-line method over the estimated useful lives of the respective assets as follows:
	Asset Category	Estimated Useful Life
		(in Years)
	Laboratory equipment		5
	Furniture and fixtures		5
	Computer equipment		3
Impairment of Long-Lived Assets	'
	Impairment of Long-Lived Assets
	Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets or related asset group may not be recoverable. Determination of recoverability is based on an estimate of discounted future cash flows resulting from the use of the asset. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the asset or asset group, the carrying amount of the asset is written down to its estimated net realizable value.
	In connection with the restructuring discussed in Note 8, “Restructuring,” the Company entered into an equipment lease agreement with Buffalo BioLabs, or BBL, effective January 1, 2014 for the equipment used by the employees transitioned to BBL. The estimated fair value of those assets using a discounted cash flow approach was $243,000. Comparing this fair value to the carrying amount of the equipment as of December 31, 2013 of $536,000 resulted in a $293,000 write-down of the assets, which was included in research and development expenses for the year ended December 31, 2013.
Restricted Cash	'
	Restricted Cash
	Restricted cash at December 31, 2013 includes certificates of deposit denominated in Russian Rubles and posted by Panacela and BioLab 612 as collateral for performance guarantees for their contracts with the Ministry of Industry and Trade of the Russian Federation. The guarantees require Panacela and BioLab 612 to satisfactorily perform their statements of work under the contracts. Both Panacela and BioLab 612 anticipate receiving the full proceeds of their deposits at the completion of the contracts, which for each contract is more than a year away. As a consequence, all of the Company’s restricted cash is classified as a noncurrent asset.
Intellectual Property	'
	Intellectual Property
	Costs related to filing and pursuing patent applications are recognized as general and administrative expenses as incurred, since the recoverability of such expenditures is uncertain. Upon marketability approval by the U.S. Food and Drug Administration, or FDA, or a respective foreign governing body, such costs will be capitalized and depreciated over the expected life of the related patent.
	During the year-ended December 31, 2011, the Company performed its periodic review of capitalized patent costs and incorporated a more restrictive standard of capitalization widely utilized in the biotechnology industry, which includes a prerequisite of the FDA marketability approval as one of several factors needed to justify the continued capitalization of costs associated with securing patents. Given that the Company is currently developing requisite data towards submission to the FDA of biological license and new drug applications in support of its existing product candidates, capitalized patent costs of approximately $1,500,000 were expensed during the year ended December 31, 2011. This item has been treated as a change in estimate in the accompanying financial statements.
Deferred Revenue	'
	Deferred Revenue
	Deferred revenue represents cash received under grants and contracts in excess of the revenue recognizable through the end of the respective financial reporting period. The revenue associated with these advances will be recognized in future periods as the applicable costs are incurred.
Accrued Warrant Liability	'
	Accrued Warrant Liability
	Certain warrants are accounted for as derivative instruments in accordance with the Financial Accounting Standards Board Accounting Standards Codification, or the Codification, on derivatives and hedging as the warrant holders, under certain change of control situations, could require settlement in cash. As such, the warrants were initially recorded as liabilities based on their fair values on the date of issuance. Subsequent changes in the value of the warrants are recorded in the statements of operations as “Change in value of warrant liability.”
	The Company’s remaining outstanding warrants were treated as equity upon issuance and continue to be treated as equity since they did not contain any mandatory redemption features or other provisions that would require a different classification of these warrant instruments outside of permanent equity.
Foreign Currency Translation	'
	Foreign Currency Translation
	The Russian ruble is the functional currency of our foreign subsidiaries, which are all located in the Russian Federation. Assets and liabilities of these subsidiaries are translated into U.S. dollars at the period-end exchange rate. Income and expense items are translated at the average exchange rates during the period. The net effect of this translation is recorded in the consolidated financial statements as accumulated other comprehensive income (loss).
Revenue Recognition	'
	Revenue Recognition
	The Company generates grant and contract revenue from two different types of contractual arrangements: cost reimbursable grants and contracts and fixed-price grants and contracts. Costs consist primarily of internal labor charges, subcontractors and materials, as well as an allocation of fringe benefits, overhead and general and administrative expenses, based on the terms of the contract. Under cost reimbursable grants and contracts, revenue is recognized during the period that the associated research and development costs are incurred. Under fixed-price grants and contracts, revenue is recognized using the percentage-of-completion method. The assumptions and estimates used in determination of the percentage-of-completion are developed in coordination with the principal investigator performing the work.
Research and Development	'
	Research and Development
	Research and development costs are expensed as incurred. Research and development costs primarily consist of salaries, fringe benefits, materials and related expenses for personnel and facility expenses. Other research and development expenses include fees paid to consultants and outside service providers, the costs of materials used in clinical trials and research and development and stock-based compensation.
Accounting for Stock-Based Compensation	'
	Accounting for Stock-Based Compensation
	The 2006 Equity Incentive Plan, as amended, or the “Plan”, authorizes CBLI to grant (i) options to purchase common stock, (ii) restricted or unrestricted stock units, and (iii) stock appreciation rights, so long as the exercise or grant price of each are at least equal to the fair market value of the stock on the date of grant. At the 2012 annual meeting of stockholders, an amendment to increase the maximum number of shares of common stock reserved for issuance under the Plan was approved, and as of December 31, 2013, an aggregate of 10.0 million shares of common stock were authorized for issuance under the Plan, of which a total of approximately 2.1 million shares of common stock remained available for future awards. A single participant cannot be awarded more than 400,000 shares annually. Awards granted under the Plan have a contractual life of no more than 10 years. The terms and conditions of equity awards (such as price, vesting schedule, term and number of shares) under the Plan are specified in an award document, and approved by compensation committee of the CBLI’s board of directors.
	The Company utilizes the Black-Scholes valuation model for estimating the fair value of all stock options granted. Set forth below are the assumptions used in valuing the stock options granted and a discussion of the Company’s methodology for developing each of the assumptions used:
		For the year ended December 31,
		2013			2012			2011
	Risk-free interest rate		.02 - 1.92	%		.65 - 1.49	%		.96 - 2.61	%
	Expected dividend yield		0	%		0	%		0	%
	Expected life		5 - 7.3 Years			5 - 6 Years			5 - 6 Years
	Expected volatility		78.62 - 89.66	%		86.58 - 92.60	%		84.28 - 92.38	%
	“Risk-free interest rate” means the range of U.S. Treasury rates with a term that most closely resembles the expected life of the option as of the date the option is granted.
	“Expected dividend yield” means the Company does not pay regular dividends on its common stock and does not anticipate paying any dividends in the foreseeable future.
	“Expected life” means the period of time that options granted are expected to remain outstanding, based wholly on the use of the simplified (safe harbor) method. The simplified method is used because the Company does not yet have adequate historical exercise information to estimate the expected life the options granted.
	“Expected volatility” means a measure of the amount by which a financial variable, such as share price, has fluctuated (historical volatility) or is expected to fluctuate (implied volatility) during a period. Expected volatility is based on the Company’s historical volatility and incorporates the volatility of the common stock of comparable companies when the expected life of the option exceeds the Company’s trading history.
	In June 2013, CBLI’s stockholders approved the 2013 Employee Stock Purchase Plan, or ESPP, which provides a means by which eligible employees of CBLI, and certain designated related corporations may be given an opportunity to purchase shares of CBLI common stock. As of December 31, 2013, there are 2.1 million shares of common stock reserved for purchase under the ESPP. The number of shares reserved for purchase under the ESPP increases on January 1 of each calendar year by the lesser of (i) 10% of the total number of shares of common stock outstanding on December 31 of the preceding year, or (ii) 200,000 shares of common stock. The ESPP allows employees to use up to 15% of their compensation to purchase shares of common stock at an amount equal to 85% of the fair market value of the our common stock on the offering date or the purchase date, whichever is less.
Income taxes	'
	Income taxes
	No income tax expense was recorded for the years ended December 31, 2013, 2012 and 2011, as the Company did not have taxable income for any of the years presented. A full valuation allowance has been recorded against the Company’s net deferred tax asset.
Earnings/(Loss) Per Share	'
	Earnings/(loss) per share
	Basic net income (loss) per share of common stock excludes dilution for potential common stock issuances and is computed by dividing net income (loss) by the weighted average number of shares outstanding for the period. Diluted net income (loss) per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. Diluted net loss per share is identical to basic net loss per share as potentially dilutive securities have been excluded from the calculation of diluted net loss per common share because the inclusion of such securities would be antidilutive.
	The Company has excluded the following outstanding warrants and options from the calculation of diluted net loss per share because all such securities were antidilutive for the periods presented:
		As of December 31,
	Common Equivalent Securities	2013			2012			2011
	Preferred Shares		—			—			—
	Warrants		10,534,245			10,377,995			12,564,193
	Options		5,564,833			5,016,966			4,117,979
	Total		16,099,078			15,394,961			16,682,172
Comprehensive Income (Loss)	'
	Comprehensive Income (Loss)
	The Company applies the Codification on comprehensive income (loss) that requires disclosure of all components of comprehensive income (loss) on an annual and interim basis. Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources.
Recently Issued Accounting Pronouncements	'
	Recently Issued Accounting Pronouncements
	From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Property, Plant, and Equipment Useful Lives	'
	Equipment is depreciated using the straight-line method over the estimated useful lives of the respective assets as follows:
	Asset Category	Estimated Useful Life
		(in Years)
	Laboratory equipment		5
	Furniture and fixtures		5
	Computer equipment		3
Summary of Assumptions Used in Valuing Stock Options Granted	'
	The Company utilizes the Black-Scholes valuation model for estimating the fair value of all stock options granted. Set forth below are the assumptions used in valuing the stock options granted and a discussion of the Company’s methodology for developing each of the assumptions used:
		For the year ended December 31,
		2013			2012			2011
	Risk-free interest rate		.02 - 1.92	%		.65 - 1.49	%		.96 - 2.61	%
	Expected dividend yield		0	%		0	%		0	%
	Expected life		5 - 7.3 Years			5 - 6 Years			5 - 6 Years
	Expected volatility		78.62 - 89.66	%		86.58 - 92.60	%		84.28 - 92.38	%
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	'
	The Company has excluded the following outstanding warrants and options from the calculation of diluted net loss per share because all such securities were antidilutive for the periods presented:
		As of December 31,
	Common Equivalent Securities	2013			2012			2011
	Preferred Shares		—			—			—
	Warrants		10,534,245			10,377,995			12,564,193
	Options		5,564,833			5,016,966			4,117,979
	Total		16,099,078			15,394,961			16,682,172

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2013
Fair Value Hierarchy for Financial Assets and Liabilities Measured on Recurring Basis	'
	The following tables represent the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2013 and December 31, 2012:
			As of December 31, 2013
			Level 1			Level 2			Level 3		Total
	Liabilities:
	Accrued warrant liability		$	—		$	—		$	1,241,311	$	1,241,311
	Compensatory stock options not yet issued (1)			—			—			309,450		309,450
	Total liabilities		$	—		$	—		$	1,550,761	$	1,550,761
			As of December 31, 2012
			Level 1			Level 2			Level 3		Total
	Liabilities:
	Accrued warrant liability		$	—		$	—		$	4,105,659	$	4,105,659
	Total liabilities		$	—		$	—		$	4,105,659	$	4,105,659
	-1	Included in accrued expenses in the accompanying consolidated balance sheets.
Schedule of Share-Based Payment Award Warrant Liability Valuation Assumptions	'
	The following are the assumptions used to measure the accrued warrant liability at December 31, 2013 and 2012, which were determined in a manner consistent with that described for grants of options to purchase common stock as set forth in Note 2, “Summary of Significant Accounting Policies”:
			December 31, 2013			December 31, 2012
	Stock Price		$	1.17		$	1.33
	Exercise Price		$	1.60 - 5.00		$	1.60 - 5.00
	Term in years			0.59 - 1.91			1.09 - 2.41
	Volatility			42.52 - 76.03	%		82.75 - 95.91	%
	Annual rate of quarterly dividends			0	%		0	%
	Discount rate- bond equivalent yield			.08 - .36	%		.17 - .29	%
Assumptions Used to Measure the Compensatory Stock Options	'
	The following are the assumptions used to measure the compensatory stock options not yet issued at December 31, 2013:
			December 31, 2013
	Stock price		$	0.72
	Term in years			5
	Volatility			75.68	%
	Annual rate of quarterly dividends			0	%
	Discount rate – bond equivalent yield			1.52	%
Summary of Changes in Fair Value of Company's Level 3 Fair Value Measurements	'
	The following table sets forth a summary of changes in the fair value of the Company’s Level 3 fair value measurements for the year ended December 31, 2013 and 2012:
			Year Ended December 31, 2013
			Accrued Warrant			Compensatory
			Liability			Stock Options
						Issued After Year
						End
	Beginning Balance		$	4,105,659		$	—
	Total (gains) or losses, realized and unrealized, included in earnings (1)(2)			(2,864,348	)		—
	Estimates and other changes in fair value			—			309,450
	Balance, December 31, 2013		$	1,241,311		$	309,450
			Year Ended December 31, 2012
			Accrued Warrant			Compensatory
			Liability			Stock Options
						Issued After Year
						End
	Beginning Balance		$	7,285,959		$	378,750
	Total (gains) or losses, realized and unrealized, included in earnings (1)(2)			(7,701,981	)		51,823
	Issuances			4,521,681			—
	Settlements			—			(430,573	)
	Balance, December 31, 2012		$	4,105,659		$	—
	-1	Unrealized gains or losses related to the accrued warrant liability were included as change in value of accrued warrant liability. There were no realized gains or losses for the years ended December 31, 2013 and 2012.
	-2	Expenses recorded for compensatory stock options not yet issued are included in research and development expense and general and administrative expense.
Summary of Unobservable Inputs in Fair Value Measurements	'
	The following table summarizes the unobservable inputs into the fair value measurements:
			December 31, 2013
	Description		Fair Value			Valuation Technique		Unobservable Input	Range
	Compensatory stock options not yet issued		$	309,450		Black-scholes pricing model		Expected term		5
								Quantity of options		696,000
	Accrued warrant liability			1,241,311		Black-scholes pricing model		Expected term		0.59 - 1.91
			$	1,550,761
Warrant [Member]	'
Assumptions Used to Measure the Compensatory Stock Options	'
	Certain warrants issued during the 2012 offering contain provisions that could require the Company to settle the warrants in cash and, accordingly, were originally recorded as a liability in the amount of $4,521,681 determined by the Black-Scholes valuation model with the following assumptions:
	Stock price		$	2.48
	Exercise price		$	3
	Term in years			2.51
	Volatility			79.7	%
	Annual rate of quarterly dividends			—
	Discount rate- bond equivalent yield			0.35	%
	Certain warrants issued in June 2011 contain provisions that could require the Company to settle the warrants in cash, and accordingly, were originally recorded as a liability in the amount of $2,525,175 determined by the Black-Scholes valuation model with the following assumptions:
	Stock price		$	4.45
	Exercise price		$	5
	Term in years			2.5
	Volatility			69.36	%
	Annual rate of quarterly dividends			—
	Discount rate- bond equivalent yield			0.53	%

Equipment_Tables

Equipment (Tables)	12 Months Ended
	Dec. 31, 2013
Property Plant And Equipment [Abstract]	'
Summary of Equipment Costs	'
	The following table summarizes the Company’s gross equipment costs for the years ended December 31, 2013 and 2012:
		As of December 31,
		2013			2012
	Lab equipment	$	1,083,463		$	1,903,533
	Computer equipment		332,386			335,264
	Furniture		528,807			523,665
			1,944,656			2,762,462
	Less accumulated depreciation		(1,486,744	)		(1,775,909	)
	Equipment, net	$	457,912		$	986,553

Noncontrolling_Interests_Table

Noncontrolling Interests (Tables)	12 Months Ended
	Dec. 31, 2013
Noncontrolling Interest [Abstract]	'
Summary of CBLI Equity Changes from Ownership Changes in Incuron	'
	The following quantifies the effects of changes in CBLI’s ownership interest in Incuron, on CBLI’s equity for the years ending December 31, 2013, 2012 and 2011:
		For the Year Ending December 31,
		2013			2012			2011
	Net loss attributable to CBLI	$	(17,262,877	)	$	(18,234,142	)	$	(4,013,670	)
	Increase in CBLI’s additional paid-in capital due to the issuance of additional membership interests to the noncontrolling interest of Incuron		—			1,081,040			176,092
	Change from net income attributable to CBLI and issuance of additional membership interests to the noncontrolling interest of Incuron	$	(17,262,877	)	$	(17,153,102	)	$	(3,837,578	)

Debt_Tables

Debt (Tables)	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Warrant Fair Value Assumptions	'
	The fair value of the warrant was calculated using the Black-Scholes option pricing model with the following assumptions:
	Risk-free interest rate		0.48	%
	Expected dividend yield		0	%
	Expected life (years)		2.5
	Expected volatility		82.29	%
Summary of Principal Payments	'
	The following schedule shows the payments for principal and the end of term charge on the Hercules loan by calendar year:
	2014	$	351,527
	2015		2,246,215
	2016		2,495,163
	2017		1,457,095
	Total	$	6,550,000

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
Schedule of Stockholders' Equity Note, Warrants or Rights	'
	The following table sets forth the changes in the number of warrants outstanding for the periods presented, exclusive of the warrants issued to Rusnano in connection with their loan to Panacela as those warrants are not exercisable until an event of default which has not occurred:
		Number of			Weighted Average		Number of Common
		Warrants			Exercise Price		Shares Exercisable Into
	Outstanding at December 31, 2011		10,121,219		$	3.76		12,564,193
	Granted		4,312,500			3		4,312,500
	Forfeited, Canceled		(4,055,724	)		5.07		(6,498,698	)
	Outstanding at December 31, 2012		10,377,995			2.94		10,377,995
	Granted		156,250			1.6		156,250
	Outstanding at December 31, 2013		10,534,245			2.7		10,534,245
Schedule of Share-Based Compensation Shares Authorized Under Warrants by Exercise Price Range	'
	The following table sets forth the details of the outstanding warrants as of December 31, 2013:
	Expiration Date	Current			Number of
		Exercise Price			Warrants
	March 2, 2015	$	1.6			935,385
	June 17, 2015		5			176,175
	February 12, 2016		1.6			929,826
	March 19, 2016		1.6			1,921,795
	March 26, 2016		1.6			634,189
	June 22, 2016		5			1,468,125
	October 24, 2017		3			4,312,500
	September 30, 2018		1.6			156,250
						10,534,245
Schedule of Share-based Compensation, Stock Options Activity	'
	The following is a summary of option award activity under the Plan for the year ended December 31, 2013:
		Year Ended December 31, 2013
		Total Stock Options			Weighted Average		Nonvested Stock			Weighted Average
		Outstanding			Exercise Price per		Options			Grant Date Fair
					Share					Value per Share
	December 31, 2012		5,016,916		$	4.54		404,500		$	2.3
	Granted		903,775			1.67		903,775			1.21
	Vested		—			—		(513,296	)		1.73
	Exercised		(9,681	)		1.28		—			—
	Forfeited, Canceled		(346,177	)		3.53		(200,500	)		1.21
	December 31, 2013		5,564,833			4.14		594,479			1.5
Schedule of Share-based Compensation, Activity	'
	The following is a summary of outstanding stock options under the Plan as of December 31, 2013:
		Stock Options			Vested Stock
		Outstanding			Options
	Quantity		5,564,833			4,970,354
	Weighted-average exercise price	$	4.14		$	4.4
	Weighted Average Remaining Contractual Term (in Years)		6.75			6.47
	Intrinsic value	$	11,592		$	11,592

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Schedule of Income (Loss) from Continuing Operations before Income Tax, Domestic and Foreign	'
	Income (loss) from continuing operations consists of the following:
		For the Year Ended December 31,
		2013			2012			2011
	US operations	$	(13,505,266	)	$	(14,317,608	)	$	(1,775,053	)
	Foreign operations		(6,624,018	)		(8,097,032	)		(3,454,672	)
		$	(20,129,284	)	$	(22,414,640	)	$	(5,229,725	)
Schedule of Deferred Tax Assets (Liabilities)	'
	Deferred tax assets (liabilities) were comprised of the following as of the periods presented below:
		As of December 31,
		2013			2012			2011
	Deferred tax assets:
	Operating loss carryforwards	$	44,120,000		$	37,642,000		$	28,972,000
	Accrued expenses		8,861,000			8,576,000			7,778,000
	Tax credit carryforwards		3,186,000			2,921,000			2,537,000
	Intellectual property		4,846,000			3,377,000			1,604,000
	Outside tax basis difference in affiliate		2,825,000			1,616,000			1,378,000
	Equipment		388,000			237,000			156,000
	Other		—			4,000			4,000
	Total deferred tax assets		64,226,000			54,373,000			42,429,000
	Deferred tax liabilities		—			—			—
	Net deferred tax asset		64,226,000			54,373,000			42,429,000
	Valuation allowance		(64,226,000	)		(54,373,000	)		(42,429,000	)
		$	—		$	—		$	—
Schedule of Effective Income Tax Rate Reconciliation	'
	The provision for income taxes differs from the amount of income tax determined by applying the applicable U.S. statutory federal income tax rate to the pretax loss from continuing operations as a result of the following differences:
		For the Year Ended December 31,
		2013			2012			2011
	Tax at the U.S. statutory rate	$	(6,810,000	)	$	(7,621,000	)	$	(1,778,000	)
	Change in value of warrant liability		(974,000	)		(2,619,000	)		(6,739,000	)
	Stock option expenses		—			—			(140,000	)
	Valuation allowance		7,723,000			10,204,000			8,639,000
	Other		61,000			36,000			18,000
		$	—		$	—		$	—
Summary of Unrecognized Tax Benefits and the Associated Interest and Penalties	'
	The following presents a roll-forward of the unrecognized tax benefits and the associated interest and penalties:
		Unrecognized			Interest
		Tax Benefits			and Penalties
	Balance at January 1, 2012	$	407,000		$	—
	Prior year tax position		—			—
	Current year tax position		—			—
	Deferred tax position		30,000			—
	Settlements with tax authorities		—			—
	Expiration of the statute of limitations		—			—
	Balance at December 31, 2012		437,000			—
	Prior year tax position		—			—
	Current year tax position		—			—
	Deferred tax position		8,000			—
	Settlements with tax authorities		—			—
	Expiration of the statute of limitations		—			—
	Balance at December 31, 2013	$	445,000		$	—

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments And Contingencies Disclosure [Abstract]	'
Schedule of Future Minimum Lease Payments for Capital Leases	'
	As of December 31, 2013, future minimum future lease payments under capital leases are as follows:
	2014	$	91,341
	2015		7,612
	Total minimum lease payments		98,953
	Interest expense related to future periods		7,797
	Present value of minimum lease payments		91,156
	Less: current portion		83,634
	Non-current portion	$	7,522
Schedule of Future Minimum Lease Payments for Operating Leases	'
	As of December 31, 2013, future minimum payments under operating leases are as follows:
	2014	$	471,925
	2015		344,580
	2016		354,918
	2017		365,565
	2018		376,532
	2019		191,048
	Total minimum lease payments	$	2,104,568

Quarterly_Financial_Data_Unaud1

Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Summary of the Quarterly Consolidated Results of Operations	'
	The following is a summary of the quarterly consolidated results of operations for the years ended December 31, 2013 and December 31, 2012:
		For the Quarter Ended
		March 31, 2013			June 30, 2013			September 30, 2013			December 31, 2013
	Revenues	$	1,367,472		$	1,613,262		$	1,635,600		$	3,871,632
	Loss from Operations		(7,447,515	)		(6,776,618	)		(5,856,468	)		(2,996,158	)
	Net Income (Loss)		(10,787,148	)		(3,886,421	)		(4,610,961	)		(844,754	)
	Net Income (Loss) Attributable to Cleveland BioLabs, Inc.		(9,764,323	)		(3,042,111	)		(4,091,196	)		(365,247	)
	Basic Earnings (Loss) Per Share Available for Common Shareholders	$	(0.22	)	$	(0.07	)	$	(0.09	)	$	(0.01	)
	Fully Diluted Earnings (Loss) Per Share Available for Common Shareholders	$	(0.22	)	$	(0.07	)	$	(0.09	)	$	(0.01	)
	Weighted Average Shares Outstanding, Basic		44,826,576			44,948,591			45,061,274			45,170,129
	Weighted Average Shares Outstanding, Diluted		44,826,576			44,948,591			45,061,274			45,170,129
		For the Quarter Ended
		March 31, 2012			30-Jun-12			September 30, 2012			December 31, 2012
	Revenues	$	931,397		$	258,237		$	219,575		$	2,161,501
	Loss from Operations		(7,481,875	)		(9,161,724	)		(7,841,541	)		(5,561,466	)
	Net Income (Loss)		(6,398,894	)		(5,906,870	)		(12,315,676	)		2,206,800
	Net Income (Loss) Attributable to Cleveland BioLabs, Inc.		(5,387,146	)		(5,078,684	)		(10,877,836	)		3,109,524
	Basic Earnings (Loss) Per Share Available for Common Shareholders	$	(0.15	)	$	(0.14	)	$	(0.30	)	$	0.07
	Fully Diluted Earnings (Loss) Per Share Available for Common Shareholders	$	(0.15	)	$	(0.14	)	$	(0.30	)	$	0.07
	Weighted Average Shares Outstanding, Basic		35,657,563			35,745,675			35,879,245			42,236,226
	Weighted Average Shares Outstanding, Diluted		35,657,563			35,745,675			35,879,245			42,565,945

Description_of_Business_Additi

Description of Business - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2013
	Subsidiary
BioLab 612 [Member]	'
Subsidiary or Equity Method Investee [Line Items]	'
Number Of wholly-owned subsidiaries	1
Incuron LLC and Panacela Labs, Inc. [Member]	'
Subsidiary or Equity Method Investee [Line Items]	'
Number of majority owned subsidiaries	2

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)

12 Months Ended

12 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2013

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Mar. 11, 2014

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Agreement

2013 ESPP Plan [Member]

Patents [Member]

Grant and Contract Revenue from U S A [Member]

Grant and Contract Revenue from U S A [Member]

Grant and Contract Revenue from U S A [Member]

Grant and Contract Revenue from Outside United States [Member]

Grant and Contract Revenue from Outside United States [Member]

Grant and Contract Revenue from Outside United States [Member]

Accounts Receivable [Member]

Buffalo BioLabs [Member]

Scenario, Previously Reported [Member]

Subsequent Event [Member]

Cash and Cash Equivalents Located Outside United States [Member]

Short Term Investments Located Outside United States [Member]

Beyond [Member]

Less Than [Member]

Majority Owned Subsidiaries [Member]

General Use [Member]

Certificates of Deposit [Member]

Certificates of Deposit [Member]

Accounting Policies [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash and cash equivalents at carrying value

$10,048,466

$25,652,083

$22,872,589

$10,918,537

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Other cash and cash equivalents at carrying value

3,500,000

13,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash and highly liquid investments maturity

'90 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Subsidiary cash total

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,000,000

'

General use cash total

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8,000,000

Short-term investments maturity

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 months

'1 year

'

'

Concentration risk percentage

'

'

'

'

'

'

26.80%

34.80%

87.60%

73.20%

65.20%

12.40%

'

'

'

'

36.00%

100.00%

'

'

'

'

Russian Ruble exchange rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

32.2792

36.2618

'

'

'

'

'

'

Decrease in company's cash and cash equivalents

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

350,557

'

'

'

'

'

'

Decrease in company's short-term investment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

29,765

'

'

'

'

'

'

Credit term

'

'

'

'

'

'

'

'

'

'

'

'

'30 days

'

'

'

'

'

'

'

'

'

Allowances for doubtful accounts

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Date of equipment lease agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

1-Jan-14

'

'

'

'

'

'

'

'

Carrying amount of the equipment

536,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of assets

243,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Write-down of the assets

293,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amortization of intangible assets

'

'

'

'

'

1,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of contractual arrangement

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based compensation arrangement by share-based payment award, number of shares authorized

10,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based compensation arrangement by share-based payment award, number of shares available for grant

2,100,000

'

'

'

2,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based compensation arrangement by share-based payment award number of shares limited per year

400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based compensation arrangement by share-based payment award, equity instruments other than options, outstanding, weighted average remaining contractual terms

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of the total number of shares of common stock outstanding of the preceding year

'

'

'

'

10.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based compensation arrangement by share-based payment award, number of shares limited per year

'

'

'

'

200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based compensation arrangement by share-based payment award, maximum employee subscription rate

'

'

'

'

15.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based compensation arrangement by share-based payment award, discount from market price, offering rate

'

'

'

'

85.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Income tax expense

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Summary_of_Significant_Account4

Summary of Significant Accounting Policies - Property, Plant,and Equipment Useful Lives (Detail)	12 Months Ended
	Dec. 31, 2013
Laboratory Equipment [Member]	'
Accounting Policies [Line Items]	'
Assets, Estimated useful life	'5 years
Furniture and Fixtures [Member]	'
Accounting Policies [Line Items]	'
Assets, Estimated useful life	'5 years
Computer Equipment [Member]	'
Accounting Policies [Line Items]	'
Assets, Estimated useful life	'3 years

Summary_of_Significant_Account5

Summary of Significant Accounting Policies - Summary of Assumptions Used in Valuing Stock Options Granted (Detail)

1 Months Ended

12 Months Ended

Oct. 31, 2012

Jun. 30, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Minimum [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Employee Stock Option [Member]

Employee Stock Option [Member]

Employee Stock Option [Member]

Employee Stock Option [Member]

Employee Stock Option [Member]

Employee Stock Option [Member]

Accounting Policies [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Risk-free interest rate

'

'

1.52%

'

0.08%

0.17%

0.02%

0.65%

0.96%

0.36%

0.29%

1.92%

1.49%

2.61%

Expected dividend yield

'

'

0.00%

0.00%

'

'

'

'

'

'

'

0.00%

0.00%

0.00%

Expected life

'2 years 6 months 4 days

'2 years 6 months

'5 years

'

'7 months 2 days

'1 year 1 month 2 days

'5 years

'5 years

'5 years

'1 year 10 months 28 days

'2 years 4 months 28 days

'7 years 3 months 18 days

'6 years

'6 years

Expected volatility

79.70%

69.36%

75.68%

'

42.52%

82.75%

78.62%

86.58%

84.28%

76.03%

95.91%

89.66%

92.60%

92.38%

Summary_of_Significant_Account6

Summary of Significant Accounting Policies - Antidilutive Securities Excluded from Computation of Earnings per Share (Detail)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Accounting Policies [Line Items]	'	'	'
Antidilutive Securities	16,099,078	15,394,961	16,682,172
Preferred Shares [Member]	'	'	'
Accounting Policies [Line Items]	'	'	'
Antidilutive Securities	'	'	'
Warrant [Member]	'	'	'
Accounting Policies [Line Items]	'	'	'
Antidilutive Securities	10,534,245	10,377,995	12,564,193
Employee Stock Option [Member]	'	'	'
Accounting Policies [Line Items]	'	'	'
Antidilutive Securities	5,564,833	5,016,966	4,117,979

Fair_Value_Measurements_Fair_V

Fair Value Measurements - Fair Value Hierarchy for Financial Assets and Liabilities Measured on Recurring Basis (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Liabilities:	'	'
Accrued warrant liability	$1,241,311	$4,105,659
Compensatory stock options not yet issued	309,450	'
Total liabilities	1,550,761	4,105,659
Level 1 [Member]	'	'
Liabilities:	'	'
Accrued warrant liability	'	'
Compensatory stock options not yet issued	'	'
Total liabilities	'	'
Level 2 [Member]	'	'
Liabilities:	'	'
Accrued warrant liability	'	'
Compensatory stock options not yet issued	'	'
Total liabilities	'	'
Level 3 [Member]	'	'
Liabilities:	'	'
Accrued warrant liability	1,241,311	4,105,659
Compensatory stock options not yet issued	309,450	'
Total liabilities	$1,550,761	$4,105,659

Fair_Value_Measurements_Schedu

Fair Value Measurements - Schedule of Share-Based Payment Award Warrant Liability Valuation Assumptions (Detail) (USD $)	1 Months Ended		12 Months Ended
	Oct. 31, 2012	Jun. 30, 2011	Dec. 31, 2013	Dec. 31, 2012
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'	'	'
Stock price	$2.48	$4.45	$0.72	'
Exercise Price	$3	$5	'	'
Term in years	'2 years 6 months 4 days	'2 years 6 months	'5 years	'
Volatility	79.70%	69.36%	75.68%	'
Annual rate of quarterly dividends	'	'	0.00%	0.00%
Discount rate- bond equivalent yield	'	'	1.52%	'
Maximum [Member]	'	'	'	'
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'	'	'
Stock price	'	'	$1.17	1.33
Exercise Price	'	'	$5	5
Term in years	'	'	'1 year 10 months 28 days	'2 years 4 months 28 days
Volatility	'	'	76.03%	95.91%
Discount rate- bond equivalent yield	'	'	0.36%	0.29%
Minimum [Member]	'	'	'	'
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'	'	'
Exercise Price	'	'	$1.60	1.6
Term in years	'	'	'7 months 2 days	'1 year 1 month 2 days
Volatility	'	'	42.52%	82.75%
Discount rate- bond equivalent yield	'	'	0.08%	0.17%

Fair_Value_Measurements_Assump

Fair Value Measurements - Assumptions Used to Measure the Compensatory Stock Options (Detail) (USD $)	1 Months Ended		12 Months Ended
	Oct. 31, 2012	Jun. 30, 2011	Dec. 31, 2013	Dec. 31, 2012
Debt Instrument Fair Value Carrying Value [Abstract]	'	'	'	'
Stock price	$2.48	$4.45	$0.72	'
Term in years	'2 years 6 months 4 days	'2 years 6 months	'5 years	'
Volatility	79.70%	69.36%	75.68%	'
Annual rate of quarterly dividends	'	'	0.00%	0.00%
Discount rate - bond equivalent yield	'	'	1.52%	'

Fair_Value_Measurements_Summar

Fair Value Measurements - Summary of Changes in Fair Value of Company's Level 3 Fair Value Measurements (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Accrued Warrant Liability [Member]	'	'
Beginning Balance	$4,105,659	$7,285,959
Total (gains) or losses, realized and unrealized, included in earnings	-2,864,348	-7,701,981
Issuances	'	4,521,681
Ending Balance	1,241,311	4,105,659
Compensatory Stock Options not Yet Issued [Member]	'	'
Beginning Balance	'	378,750
Total (gains) or losses, realized and unrealized, included in earnings	'	51,823
Estimates and other changes in fair value	309,450	'
Settlements	'	-430,573
Ending Balance	$309,450	'

Fair_Value_Measurements_Summar1

Fair Value Measurements - Summary of Changes in Fair Value of Company's Level 3 Fair Value Measurements (Parenthetical) (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Debt Instrument Fair Value Carrying Value [Abstract]	'	'
Unrealized gains or losses	$0	$0

Fair_Value_Measurements_Additi

Fair Value Measurements - Additional Information (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2013
			Accrued Warrant Liability [Member]	Compensatory Stock Options not Yet Issued [Member]
Assets or liabilities	$0	$0	'	'
Increase in expected term	'	'	10.00%	'
Increase in accrued warrant liability with increase in expected term	'	'	22.00%	'
Decrease in expected term	'	'	10.00%	'
Decrease in accrued warrant liability with decrease in expected term	'	'	16.00%	'
Increase in stock price	'	'	10.00%	'
Increase in accrued warrant liability with increase in stock price	'	'	32.00%	'
Decrease in stock price	'	'	10.00%	'
Decrease in accrued warrant liability with decrease in stock price	'	'	26.00%	'
Increase or decrease in expected term	'	'	'	10.00%
Increase or decrease in amount accrued with expected term change	'	'	'	6.00%
Increase or decrease in stock price	'	'	'	10.00%
Increase or decrease in amount accrued with stock price change	'	'	'	10.00%

Fair_Value_Measurements_Summar2

Fair Value Measurements - Summary of Unobservable Inputs in Fair Value Measurements (Detail) (USD $)	9 Months Ended			12 Months Ended
	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013
				Employee Stock Option [Member]	Employee Stock Option [Member]	Accrued Warrant Liability [Member]	Accrued Warrant Liability [Member]	Accrued Warrant Liability [Member]	Fair Value [Member]
					Maximum [Member]		Maximum [Member]	Minimum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'	'	'	'	'	'	'	'
Fair Value	'	$1,550,761	'	$309,450	'	$1,241,311	'	'	'
Valuation Technique	'	'	'	'Black-scholes pricing model	'	'Black-scholes pricing model	'	'	'
Range	'2 years 6 months	'	'	'	'5 years	'	'1 year 10 months 28 days	'7 months 2 days	'
Unobservable Input	'	'	'	'Expected term	'	'Expected term	'	'	'
Quantity of options	'	5,564,833	5,016,916	5,564,833	'	'	'	'	696,000

Equipment_Summary_of_Equipment

Equipment - Summary of Equipment Costs (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]	'	'
Property, plant, and equipment	$1,944,656	$2,762,462
Less accumulated depreciation	-1,486,744	-1,775,909
Equipment, net	457,912	986,553
Lab Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant, and equipment	1,083,463	1,903,533
Computer Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant, and equipment	332,386	335,264
Furniture and Fixtures [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant, and equipment	$528,807	$523,665

Noncontrolling_Interests_Addit

Noncontrolling Interests - Additional Information (Detail)

12 Months Ended

0 Months Ended

0 Months Ended

0 Months Ended

12 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2013

Oct. 04, 2011

Dec. 31, 2013

31-May-12

31-May-12

Mar. 14, 2011

Mar. 14, 2011

Jan. 20, 2011

Jan. 20, 2011

Oct. 04, 2011

Dec. 31, 2013

Sep. 03, 2013

Oct. 04, 2011

31-May-12

31-May-12

Dec. 31, 2013

Mar. 14, 2011

Jan. 20, 2011

Dec. 31, 2013

Jan. 20, 2011

Mar. 14, 2011

Panacela [Member]

C B L I [Member]

C B L I [Member]

Bioprocess Capital Ventures [Member]

Bioprocess Capital Ventures [Member]

Bioprocess Capital Ventures [Member]

Bioprocess Capital Ventures [Member]

Bioprocess Capital Ventures [Member]

Bioprocess Capital Ventures [Member]

Rusnano [Member]

Rusnano [Member]

Rusnano [Member]

Rusnano [Member]

Increased To [Member]

Decreased To [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

USD ($)

USD ($)

Incuron, LLC [Member]

Incuron, LLC [Member]

Incuron, LLC [Member]

Incuron, LLC [Member]

Incuron, LLC [Member]

Incuron, LLC [Member]

USD ($)

USD ($)

USD ($)

Panacela [Member]

Bioprocess Capital Ventures [Member]

C B L I [Member]

C B L I [Member]

Bioprocess Capital Ventures [Member]

C B L I [Member]

Bioprocess Capital Ventures [Member]

USD ($)

RUB

USD ($)

RUB

USD ($)

RUB

USD ($)

Noncontrolling Interest [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payments to Acquire Additional Interest in Subsidiaries

'

'

'

'

$5,900,000

194,000,000

$100,000

1,730,000

$2,300,000

68,000,000

$17,000,000

'

'

'

'

'

'

'

'

'

'

'

Noncontrolling interest, ownership percentage by noncontrolling owners

'

'

'

54.60%

'

'

'

'

'

'

'

'

'

'

40.80%

'

'

'

16.10%

'

'

24.20%

Equity method investment, ownership percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

59.20%

'

75.80%

'

'

83.90%

'

Payments to Acquire Interest in Subsidiaries and Affiliates (in Dollars)

'

'

3,000,000

'

'

'

'

'

'

'

'

'

'

9,000,000

'

'

'

'

'

'

'

'

Debt Instrument, Face Amount

'

'

'

'

'

'

'

'

'

'

'

'

1,500,000

'

'

'

'

'

'

'

'

'

Amount available to be invested at option

'

'

'

'

'

'

'

'

'

'

'

$15,500,000

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Redemption Price Per Share (in Dollars per share)

'

$1,057

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercisable Price Percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20.00%

'

'

40.00%

'

'

Expiry date of issuance price of preferred stock

'2013-10

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Noncontrolling_Interests_Summa

Noncontrolling Interests - Summary of CBLI Equity Changes from Ownership Changes in Incuron (Detail) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Noncontrolling Interest [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Net loss attributable to CBLI	($365,247)	($4,091,196)	($3,042,111)	($9,764,323)	$3,109,524	($10,877,836)	($5,078,684)	($5,387,146)	($17,262,877)	($18,234,142)	($4,013,670)
Increase in CBLI's additional paid-in capital due to the issuance of additional membership interests to the noncontrolling interest of Incuron	'	'	'	'	'	'	'	'	'	1,081,040	176,092
Change from net income attributable to CBLI and issuance of additional membership interests to the noncontrolling interest of Incuron	'	'	'	'	'	'	'	'	($17,262,877)	($17,153,102)	($3,837,578)

Debt_Additional_Information_De

Debt - Additional Information (Detail) (USD $)

12 Months Ended

0 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

Dec. 31, 2013

Sep. 30, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Sep. 30, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Sep. 30, 2013

Sep. 30, 2013

Panacela Loan [Member]

Panacela Loan [Member]

Hercules Loan Agreement [Member]

Minimum [Member]

Maximum [Member]

Hercules Technology II, L.P. [Member]

Hercules Technology II, L.P. [Member]

Hercules Technology II, L.P. [Member]

Hercules Technology II, L.P. [Member]

Hercules Technology II, L.P. [Member]

Hercules Technology II, L.P. [Member]

Hercules Technology II, L.P. [Member]

Hercules Technology II, L.P. [Member]

Hercules Technology II, L.P. [Member]

Loan Agreement [Member]

Loan Agreement [Member]

Warrant [Member]

Facility Fee [Member]

Payment [Member]

Minimum [Member]

Maximum [Member]

Interest Only Payments [Member]

Principle And Interest Payments [Member]

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument, Description of variable Rate Basis

'

'

'

'

'

'

'

'Prime

'

'

'

'

'

'

'

Debt Instrument, Face Amount

'

$1,530,000

'

'

'

'

$6,000,000

$6,000,000

'

'

'

'

'

'

'

Proceeds from Notes Payable

'

'

'

'

'

'

'

5,900,000

'

'

'

'

'

'

'

Debt Instrument, Interest Rate, Stated Percentage rate Range, Minimum

'

'

'

'

'

'

'

10.45%

'

'

'

'

'

'

'

Debt Instrument, Basis Spread on variable rate

'

'

'

'

'

'

'

4.25%

'

'

'

'

'

'

'

Debt Instrument, Frequency of Periodic Payment

'

'

'

'

'

'

'

'

'

'

'

'

'

'12

'27

Debt Instrument Penalty rate

'

'

'

'

'

'

'

'

'

'

'

0.01

0.03

'

'

Equity Private Placement

'

'

'

'

'

'

'

'

'

'

'

'

1,000,000

'

'

Warrant term

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)

'

'

'

'

'

'

156,250

'

'

'

'

'

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights

'

'

1.694

'

1.6

2

1.6

'

'

'

'

'

'

'

'

Fair value of warrants issued in connection with debt

117,999

'

'

'

'

'

'

'

117,999

'

'

'

'

'

'

Debt Instrument, Unamortized Discount

'

'

'

'

'

'

'

'

'

100,000

550,000

'

'

'

'

Debt Issuance Cost

'

'

'

'

'

'

102,000

'

'

'

'

'

'

'

'

Debt Instrument, Interest rate, Effective Percentage

'

'

'

'

'

'

16.60%

'

'

'

'

'

'

'

'

Debt Instrument, interest Rate, stated percentage

'

16.30%

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Convertible, Conversion Price (in Dollars per Share

'

$1,057

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Convertible, Beneficial Conversion Feature

'

0.75

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Assignment Percentage

'

'

69.20%

'

'

'

'

'

'

'

'

'

'

'

'

Interest expense included in interest and other income (expense)

'

'

$81,142

$256,970

'

'

'

'

'

'

'

'

'

'

'

Debt_Warrant_Fair_Value_Assump

Debt - Warrant Fair Value Assumptions (Detail)	9 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]	'
Risk-free interest rate	0.48%
Expected dividend yield	0.00%
Expected life (years)	'2 years 6 months
Expected volatility	82.29%

Debt_Summary_of_Principal_Paym

Debt - Summary of Principal Payments (Detail) (USD $)	Dec. 31, 2013
Total	$7,121,388
Notes Payable To Hercules Technology II, L.P. [Member]	'
2014	351,527
2015	2,246,215
2016	2,495,163
2017	1,457,095
Total	$6,550,000

Stockholders_Equity_Additional

Stockholder's Equity - Additional Information (Detail) (USD $)

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

Oct. 31, 2012

Jun. 30, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Jun. 30, 2011

Dec. 31, 2012

Dec. 31, 2011

Oct. 31, 2012

Oct. 31, 2012

Jun. 30, 2011

Jun. 30, 2011

Jan. 16, 2014

Jan. 31, 2014

Jun. 30, 2011

Jun. 30, 2011

Jun. 30, 2011

Oct. 31, 2012

Oct. 31, 2012

Jan. 31, 2014

Jan. 16, 2014

Jan. 31, 2014

Jan. 16, 2014

Oct. 31, 2012

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Warrant [Member]

Warrant [Member]

Placement Agent And Financial Advisor [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Unit Consisting of I [Member]

Unit Consisting of II [Member]

Unit Consisting of III [Member]

From [Member]

To [Member]

Maximum [Member]

Maximum [Member]

Minimum [Member]

Minimum [Member]

Per Whole Share [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of units in public offering

7,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unit price

$2

$4

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of common stock share of each unit

1

'

'

'

'

'

'

'

'

'

'

'

'

'

1

'

'

'

'

'

'

'

'

'

Class of warrant or right, number of securities called by each warrant or right

'

'

'

'

'

'

'

'

0.5

'

'

'

'

'

'

0.25

0.25

'

'

'

'

'

'

'

Common stock, par value

$0.01

'

$0.01

$0.01

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants issued during the period, price per warrant

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4.5

5

4

2

1.6

1.6

1.22

1.22

3

Underwriters option, days to exercise

'30 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of warrant or right, number of securities called by warrants or rights

'

'

'

'

'

'

'

'

1,125,000

562,500

2,936,250

176,175

'

'

'

'

'

'

'

'

'

'

'

'

Over-allotment price per share

'

'

'

'

'

'

'

'

$2.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Over-allotment price per warrant to purchase a whole share

'

'

'

'

'

'

'

'

'

0.0094

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants issued to underwriter

562,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock issue during period, shares new issues

1,025,000

'

'

'

'

5,872,500

8,525,000

5,872,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants not settleable in cash, fair value disclosure

'

$2,525,175

'

$4,521,681

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from issuance of common stock

'

23,500,000

'

15,675,727

21,946,801

'

'

'

'

'

'

'

6,400,000

'

'

'

'

'

'

'

'

'

'

'

Number of Warrants

'

'

10,534,245

'

'

'

'

'

'

'

'

'

'

156,250

'

'

'

'

'

'

'

'

'

'

Share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures

'

'

903,775

1,132,383

1,459,393

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value

'

'

$1.21

$1.32

$4.04

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based compensation arrangement by share-based payment award, options, vested in period, fair value

'

'

887,603

1,549,888

5,381,855

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based compensation arrangement by share-based payment award, options, exercises in period, total intrinsic value

'

'

5,736

1,485

818,723

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Employee Service Share-based Compensation, non-vested awards, total compensation cost not yet recognized

'

'

$445,647

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Employee Service Share-based Compensation, non-vested awards, total compensation cost not yet recognized, period for recognition

'

'

'9 months 4 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stockholders_Equity_Warrants_D

Stockholders' Equity - Warrants Determined by the Black-Scholes Valuation Model with the Following Assumptions (Detail) (USD $)	1 Months Ended		12 Months Ended
	Oct. 31, 2012	Jun. 30, 2011	Dec. 31, 2013	Dec. 31, 2012
Equity [Abstract]	'	'	'	'
Stock price	$2.48	$4.45	$0.72	'
Exercise Price	$3	$5	'	'
Term in years	'2 years 6 months 4 days	'2 years 6 months	'5 years	'
Volatility	79.70%	69.36%	75.68%	'
Annual rate of quarterly dividends	'	'	0.00%	0.00%
Discount rate- bond equivalent yield	0.35%	0.53%	'	'

Stockholders_Equity_Schedule_o

Stockholders' Equity - Schedule of Stockholders' Equity Note, Warrants or Rights (Detail) (USD $)	Dec. 31, 2013	Oct. 31, 2012	Jun. 30, 2011	Dec. 31, 2013	Dec. 31, 2012
		Warrant [Member]	Warrant [Member]	Warrant [Member]	Warrant [Member]
				Rusnano [Member]	Rusnano [Member]
Class of Warrant or Right [Line Items]	'	'	'	'	'
Number of Warrants Outstanding, Beginning balance	10,534,245	'	'	10,377,995	10,121,219
Number of Warrants, Granted	'	'	'	156,250	4,312,500
Number of Warrants, Forfeited, Canceled	'	'	'	'	-4,055,724
Number of Warrants Outstanding, Ending balance	10,534,245	'	'	10,534,245	10,377,995
Weighted Average Exercise Price, Outstanding, Beginning balance	'	'	'	2.94	3.76
Weighted Average Exercise Price, Granted	'	'	'	$1.60	$3
Weighted Average Exercise Price, Forfeited, Canceled	'	'	'	'	$5.07
Weighted Average Exercise Price, Outstanding, Ending balance	'	'	'	2.7	2.94
Number of Common Shares Exercisable Into Outstanding, Beginning balance	'	562,500	2,936,250	10,377,995	12,564,193
Number of Common Shares Exercisable Into, Granted	'	'	'	156,250	4,312,500
Number of Common Shares Exercisable Into, Forfeited, Canceled	'	'	'	'	-6,498,698
Number of Common Shares Exercisable Into Outstanding, Ending balance	'	562,500	2,936,250	10,534,245	10,377,995

Stockholders_Equity_Schedule_o1

Stockholders' Equity - Schedule of Share-Based Compensation Shares Authorized under Warrants by Exercise Price Range (Detail)	Dec. 31, 2013
Class of Warrant or Right [Line Items]	'
Number of Warrants	10,534,245
Expiration Date One [Member]	'
Class of Warrant or Right [Line Items]	'
Expiration Date	2-Mar-15
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Share)	1.6
Number of Warrants	935,385
Expiration Date Two [Member]	'
Class of Warrant or Right [Line Items]	'
Expiration Date	17-Jun-15
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Share)	5
Number of Warrants	176,175
Expiration Date Three [Member]	'
Class of Warrant or Right [Line Items]	'
Expiration Date	12-Feb-16
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Share)	1.6
Number of Warrants	929,826
Expiration Date Four [Member]	'
Class of Warrant or Right [Line Items]	'
Expiration Date	19-Mar-16
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Share)	1.6
Number of Warrants	1,921,795
Expiration Date Five [Member]	'
Class of Warrant or Right [Line Items]	'
Expiration Date	26-Mar-16
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Share)	1.6
Number of Warrants	634,189
Expiration Date Six [Member]	'
Class of Warrant or Right [Line Items]	'
Expiration Date	22-Jun-16
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Share)	5
Number of Warrants	1,468,125
Expiration Date Seven [Member]	'
Class of Warrant or Right [Line Items]	'
Expiration Date	24-Oct-17
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Share)	3
Number of Warrants	4,312,500
Expiration Date Eight [Member]	'
Class of Warrant or Right [Line Items]	'
Expiration Date	30-Sep-18
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Share)	1.6
Number of Warrants	156,250

Stockholders_Equity_Schedule_o2

Stockholders' Equity - Schedule of Share-Based Compensation, Stock Options, Activity (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Equity [Abstract]	'	'	'
Total Stock Options Outstanding, Beginning balance	5,016,916	'	'
Total Stock Options Outstanding, Granted	903,775	'	'
Total Stock Options Outstanding, Exercised	-9,681	'	'
Total Stock Options Outstanding, Forfeited, Canceled	-346,177	'	'
Total Stock Options Outstanding, Ending balance	5,564,833	5,016,916	'
Weighted Average Exercise Price per Share, Beginning balance	$4.54	'	'
Weighted Average Exercise Price per Share, Granted	$1.67	'	'
Weighted Average Exercise Price per Share, Exercised	$1.28	'	'
Weighted Average Exercise Price per Share, Forfeited, Canceled	$3.53	'	'
Weighted Average Exercise Price per Share, Ending balance	$4.14	$4.54	'
Nonvested Stock Options, Beginning balance	404,500	'	'
Nonvested Stock Options, Granted	903,775	'	'
Nonvested Stock Options, Vested	-513,296	'	'
Nonvested Stock Options, Forfeited, Canceled	-200,500	'	'
Nonvested Stock Options, Ending balance	594,479	404,500	'
Weighted Average Grant Date Fair Value per Share, Beginning balance	$2.30	'	'
Weighted Average Grant Date Fair Value per Share, Granted	$1.21	$1.32	$4.04
Weighted Average Grant Date Fair Value per Share, Vested	$1.73	'	'
Weighted Average Grant Date Fair Value per Share, Forfeited, Canceled	$1.21	'	'
Weighted Average Grant Date Fair Value per Share, Ending balance	$1.50	$2.30	'

Stockholders_Equity_Schedule_o3

Stockholder's Equity - Schedule of Share-based Compensation, Activity (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
			Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Quantity	5,564,833	5,016,916	5,564,833
Weighted-average exercise price	$4.14	$4.54	$4.14
Weighted Average Remaining Contractual Term (in Years)	'	'	'6 years 9 months 0 days
Intrinsic value	'	'	$11,592
Quantity	'	'	4,970,354
Weighted-average exercise price	'	'	$4.40
Weighted Average Remaining Contractual Term (in Years)	'	'	'6 years 5 months 19 days
Intrinsic value	'	'	$11,592

Restructuring_Additional_infor

Restructuring - Additional information (Detail) (USD $)	0 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2013
	Employees
Laboratory transferred	26	'
Facilities reserve	'	$100,000
Write-down of the assets	'	293,000
One-Time Employee Transition Costs [Member]	'	'
Employee transition costs	'	101,000
Other Restructuring [Member]	'	'
Facilities reserve	'	$112,000

Significant_Alliances_and_Rela1

Significant Alliances and Related Parties - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Related Party Transaction [Line Items]	'	'	'
Research and development expense	$19,525,950	$22,501,805	$22,788,887
Consultant [Member]	'	'	'
Related Party Transaction [Line Items]	'	'	'
Related party transaction, expenses from transactions with related party	202,843	200,695	186,224
Due to related parties, current	62,059	28,245	'
Consultant [Member] | Stock Based Compensation [Member]	'	'	'
Related Party Transaction [Line Items]	'	'	'
Related party transaction, amounts of transaction	164,661	32,659	109,137
Consultant [Member] | Bonus [Member]	'	'	'
Related Party Transaction [Line Items]	'	'	'
Related party transaction, expenses from transactions with related party	0	0	24,476
Consultant [Member] | Accrued Bonus A Compensation Stock Option Not Yet Issued [Member]	'	'	'
Related Party Transaction [Line Items]	'	'	'
Related party transaction, amounts of transaction	66,692	24,476	'
Entities Affiliated with Consultant [Member]	'	'	'
Related Party Transaction [Line Items]	'	'	'
Revenue from related parties	0	0	'
Research and development expense	29,607	0	0
Entities Affiliated with Consultant [Member] | Other Income [Member]	'	'	'
Related Party Transaction [Line Items]	'	'	'
Revenue from related parties	217,347	407,395	'
Buffalo BioLabs [Member]	'	'	'
Related Party Transaction [Line Items]	'	'	'
Accounts payable owed	111,356	'	'
Revenue from related parties	64,362	6,500	'
Research and development expense	419,284	'	'
R P C I [Member]	'	'	'
Related Party Transaction [Line Items]	'	'	'
Revenue from related parties	0	0	2,317,218
Related party transaction, expenses from transactions with related party	2,323,078	3,876,073	2,689,503
Accounts payable owed	172,295	900,300	'
Due to related parties, current	491,397	553,644	'
C C F [Member]	'	'	'
Related Party Transaction [Line Items]	'	'	'
Related party transaction, expenses from transactions with related party	7,516	4,804	2,558
Due to related parties, current	0	0	'
Related party transaction, amounts of transaction	0	100,000	100,000
Royalty or sublicense royalty payments	$0	$0	$0

Income_Taxes_Schedule_of_Incom

Income Taxes - Schedule of Income (Loss) from Continuing Operations before Income Tax, Domestic and Foreign (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]	'	'	'
US operations	($13,505,266)	($14,317,608)	($1,775,053)
Foreign operations	-6,624,018	-8,097,032	-3,454,672
Total	($20,129,284)	($22,414,640)	($5,229,725)

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Line Items]	'	'	'
Income tax expense (benefit), continuing operations	'	'	'
Deferred tax assets, tax credit carryforwards	3,186,000	2,921,000	2,537,000
Expire 2023 [Member]	'	'	'
Income Tax Disclosure [Line Items]	'	'	'
Deferred tax assets, operating loss carryforwards, domestic	109,919,000	'	'
Expire 2027 [Member]	'	'	'
Income Tax Disclosure [Line Items]	'	'	'
Deferred tax assets, operating loss carryforwards, state and local	99,930,000	'	'
New York State [Member]	'	'	'
Income Tax Disclosure [Line Items]	'	'	'
Proceeds from income tax refunds	62,000	532,000	367,000
Expire 2024 [Member]	'	'	'
Income Tax Disclosure [Line Items]	'	'	'
Deferred tax assets, tax credit carryforwards	3,313,000	'	'
Expire 2022 [Member]	'	'	'
Income Tax Disclosure [Line Items]	'	'	'
Deferred tax assets, operating loss carryforwards, domestic	$318,000	'	'

Income_Taxes_Schedule_of_Defer

Income Taxes - Schedule of Deferred Tax Assets and (Liabilities) (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Deferred tax assets:	'	'	'
Operating loss carryforwards	$44,120,000	$37,642,000	$28,972,000
Accrued expenses	8,861,000	8,576,000	7,778,000
Tax credit carryforwards	3,186,000	2,921,000	2,537,000
Intellectual property	4,846,000	3,377,000	1,604,000
Outside tax basis difference in affiliate	2,825,000	1,616,000	1,378,000
Equipment	388,000	237,000	156,000
Other	'	4,000	4,000
Total deferred tax assets	64,226,000	54,373,000	42,429,000
Deferred tax liabilities	'	'	'
Net deferred tax asset	64,226,000	54,373,000	42,429,000
Valuation allowance	-64,226,000	-54,373,000	-42,429,000
Total deferred tax assets (liabilities)	'	'	'

Income_Taxes_Schedule_of_Effec

Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]	'	'	'
Tax at the U.S. statutory rate	($6,810,000)	($7,621,000)	($1,778,000)
Change in value of warrant liability	-974,000	-2,619,000	-6,739,000
Stock option expenses	'	'	-140,000
Valuation allowance	7,723,000	10,204,000	8,639,000
Other	61,000	36,000	18,000
Total	'	'	'

Income_Taxes_Summary_of_Unreco

Income Taxes - Summary of Unrecognized Tax Benefits and the Associated Interest and Penalties (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]	'	'
Beginning balance, Unrecognized tax benefits	$437,000	$407,000
Prior year tax position, Unrecognized tax benefits	'	'
Current year tax position, Unrecognized tax benefits	'	'
Deferred tax position, Unrecognized tax benefits	8,000	30,000
Settlements with tax authorities, Unrecognized tax benefits	'	'
Expiration of the statute of limitations, Unrecognized tax benefits	'	'
Ending balance, Unrecognized tax benefits	445,000	437,000
Beginning balance, Interest and penalties	'	'
Prior year tax position, Interest and penalties	'	'
Current year tax position, Interest and penalties	'	'
Deferred tax position, Interest and penalties	'	'
Settlements with tax authorities, Interest and penalties	'	'
Expiration of the statute of limitations, Interest and penalties	'	'
Ending balance at December, Interest and penalties	'	'

Employee_Benefit_Plan_Addition

Employee Benefit Plan - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Compensation And Retirement Disclosure [Abstract]	'	'	'
Defined contribution plan, maximum annual contribution per employee, percent	4.00%	'	'
Defined contribution plan, employer discretionary contribution amount	$196,257	$201,510	$182,669

Commitments_and_Contingencies_1

Commitments and Contingencies - Additional Information (Detail) (USD $)	1 Months Ended	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
			Agreement
Commitments And Contingencies [Line Items]	'	'	'	'
Number of Agreements	'	'	5	'
Milestone payment & royalties	$0	'	$0	$0
Unconditional purchase obligation	'	1,024,477	'	'
Upfront payment	82,983	'	'	'
Capital lease monthly payment	'	7,616	'	'
Capital lease term	'36 months	'	'	'
Debt instrument, periodic payment	'	78,125	52,410	'
Impairment loss	'	105,491	'	'
Gross cost and carrying value adjustment	'	87,468	'	'
Debt instrument, periodic payment, interest	'	20,827	23,708	'
Accumulated depreciation for leased equipment	'	0	50,779	'
Operating lease year of start	'	'2014	'	'
Operating lease year of end	'	'2019	'	'
Operating leases, rent expense	'	511,029	459,150	396,667
Scientific Equipment [Member]	'	'	'	'
Commitments And Contingencies [Line Items]	'	'	'	'
Capital lease obligations	$304,673	'	'	$304,673

Commitments_and_Contingencies_2

Commitments and Contingencies - Schedule of Future Minimum Lease Payments for Capital Leases (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Leases [Abstract]	'	'
2014	$91,341	'
2015	7,612	'
Total minimum lease payments	98,953	'
Interest expense related to future periods	7,797	'
Present value of minimum lease payments	91,156	'
Less: current portion	83,634	71,679
Non-current portion	$7,522	$97,602

Commitments_and_Contingencies_3

Commitments and Contingencies - Schedule of Future Minimum Lease Payments for Operating Leases (Detail) (USD $)	Dec. 31, 2013
Leases [Abstract]	'
2014	$471,925
2015	344,580
2016	354,918
2017	365,565
2018	376,532
2019	191,048
Total minimum lease payments	$2,104,568

Quarterly_Financial_Data_Summa

Quarterly Financial Data - Summary of the Quarterly Consolidated Results of Operations (Detail) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Quarterly Financial Information Disclosure [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Revenues	$3,871,632	$1,635,600	$1,613,262	$1,367,472	$2,161,501	$219,575	$258,237	$931,397	$8,487,966	$3,570,710	$8,790,209
Loss from Operations	-2,996,158	-5,856,468	-6,776,618	-7,447,515	-5,561,466	-7,841,541	-9,161,724	-7,481,875	-23,076,759	-30,046,606	-25,105,171
Net income (loss)	-844,754	-4,610,961	-3,886,421	-10,787,148	2,206,800	-12,315,676	-5,906,870	-6,398,894	-20,129,284	-22,414,640	-5,229,725
Net Income (Loss) Attributable to Cleveland BioLabs, Inc.	($365,247)	($4,091,196)	($3,042,111)	($9,764,323)	$3,109,524	($10,877,836)	($5,078,684)	($5,387,146)	($17,262,877)	($18,234,142)	($4,013,670)
Basic Earnings (Loss) Per Share Available for Common Shareholders	($0.01)	($0.09)	($0.07)	($0.22)	$0.07	($0.30)	($0.14)	($0.15)	'	'	'
Fully Diluted Earnings (Loss) Per Share Available for Common Shareholders	($0.01)	($0.09)	($0.07)	($0.22)	$0.07	($0.30)	($0.14)	($0.15)	'	'	'
Weighted Average Shares Outstanding, Basic	45,170,129	45,061,274	44,948,591	44,826,576	42,236,226	35,879,245	35,745,675	35,657,563	'	'	'
Weighted Average Shares Outstanding, Diluted	45,170,129	45,061,274	44,948,591	44,826,576	42,565,945	35,879,245	35,745,675	35,657,563	'	'	'

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Detail) (USD $)

1 Months Ended

12 Months Ended

0 Months Ended

0 Months Ended

Jun. 30, 2011

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Oct. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Feb. 20, 2014

Jan. 16, 2014

Jan. 31, 2014

Jan. 16, 2014

Jan. 31, 2014

Jan. 16, 2014

Jan. 16, 2014

Jan. 16, 2014

Jan. 16, 2014

Jan. 16, 2014

Jan. 16, 2014

Jan. 16, 2014

Jan. 16, 2014

Maximum [Member]

Maximum [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Plaintiff

Maximum [Member]

Maximum [Member]

Minimum [Member]

Minimum [Member]

Series A [Member]

Series B [Member]

Series-A Placement Agent Warrants [Member]

Series-A Placement Agent Warrants [Member]

Series-B Placement Agent Warrants [Member]

Series-B Placement Agent Warrants [Member]

Common Stock [Member]

Series A [Member]

Series B [Member]

Subsequent Event [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Public offering shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,737,706

Common stock price

$4.45

'

'

$0.72

$2.48

$1.17

$1.33

'

'

'

'

'

'

'

'

'

'

'

'

$1.22

Proceeds from common stock

$23,500,000

$15,675,727

$21,946,801

'

'

'

'

'

$6,400,000

'

'

'

'

'

'

'

'

'

'

'

Additional warrants issued

'

'

'

'

'

'

'

'

'

'

'

'

'

2,868,853

2,868,853

86,066

'

86,066

'

'

Warrants exercise price

'

'

'

'

'

'

'

'

'

1.6

1.6

1.22

1.22

1.22

1.22

1.22

'

1.22

'

'

Warrant expiration period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'18 months

'

Class of warrants or right

'

'

'

'

'

'

'

'

4,421,195

'

'

'

'

'

'

'

'

'

'

'

Number of plaintiffs

'

'

'

'

'

'

'

2

'

'

'

'

'

'

'

'

'

'

'

'

Litigation settlement amount

'

'

'

'

'

'

'

$2,000,000

'

'

'

'

'

'

'

'

'

'

'

'